NWO Homepage by nikeborome

VIEWS: 358 PAGES: 79

									IMDI.NL Singapore


  Eras Draaijers
Table of Contents

Table of Contents.......................................................................................................................... 2

1. Introduction.............................................................................................................................. 3

2. Background and Framework....................................................................................................... 5

   2.1 Priority Medical Devices for the Netherlands, driven by care demand ..................................... 5

      2.1.1 The Health Care R&D Infrastructure in the Netherlands ................................................... 5

      2.1.2 Social Demand in the Netherlands: Capacity problem of an aging society ......................... 5

      2.1.3 IMDI.NL: Building on Existing Strengths in Strategic Areas ................................................ 6

   2.2 Singapore Biotechnology: increasing economic competitiveness ............................................ 8

      2.2.1 R&D Infrastructure ........................................................................................................ 8

      2.2.2 Economic Incentive: Diversification ................................................................................ 8

      2.2.3 Bioscience Initiative: a big push approach ....................................................................... 9

3. Singapore’s medical technology cluster .................................................................................... 11

   3.1 General ............................................................................................................................. 11

   3.2 Institutes........................................................................................................................... 11

4. Translation of research into innovative medical devices............................................................. 16

   4.1 Medical device innovation.................................................................................................. 16

   4.2 Innovation programs.......................................................................................................... 17

5. Conclusions............................................................................................................................. 20

6. Acknowledgements ................................................................................................................. 21

7. References.............................................................................................................................. 22

Appendices................................................................................................................................. 23

   A1 The patent analysis............................................................................................................. 23

   A2 Patent Applications............................................................................................................. 25

   A3 Patent Descriptions per Institute ......................................................................................... 29

   A4 Profiles Key Research Institutes ........................................................................................... 38
1. Introduction

This report analyzes the R&D infrastructure in Singapore in the medical devices field. It is part of the
Innovative Medical Devices Initiative NL (IMDI.NL) thematic program that aims to focus the
Netherlands’ R&D infrastructure for medical devices on health care demands and economic growth
(1). The study is a collaboration between the Netherlands Organization for Scientific Research (N WO),
and the Netherlands Office for Science & Technology at the Embassy in Singapore.

In the year 2000, a long-term initiative was launched to develop Life Sciences as the fourth pillar of
Singapore’s industries (2). From a virtually non-existent infrastructure the government aimed to build
an entire biotechnology cluster throughout its entire value chain: From basic research to clinical trials,
product development, full-scale manufacturing and health care delivery. Today, a biotechnology
cluster has emerged, mostly focused on pharmaceuticals, but with a rapidly growing medical
technology sector.


The aim of this study is to gain insight in the Singaporean medical device R&D infrastructure, or more
specifically to:

    1. Identify key Singaporean institutes that structurally perform R&D in the medical device field.
    2. Investigate developments and trends in the upcoming Singaporean medical device sector.
    3. Gain insight in how Singapore faces the challenge to translate scientific findings into
       innovative medical devices.


Focus is on developments in three technological fields, defined under the IMDI.NL thematic program,
that facilitate demands in health care while building on research excellence present in the

    1. Minimally invasive techniques,
    2. Medical imaging, and
    3. Extra-mural care


The next chapter gives some background information on the Dutch IMDI.NL initiative and the
Singaporean initiatives aimed at building their medical technology cluster as part of a larger
biotechnology ecosystem. The chapter briefly describes the initiators, aims and approaches of both

Chapter three describes Singapore’s achievements so far in its attempt to build a medical technology
cluster. It gives some indicators of R&D efforts, also it gives a brief overview of what parts of the
value chain have been established so far.

Chapter four looks more specifically at the medical device innovation process. How will Singapore
face the challenges involved with translating scientific findings into medical solutions?
Chapter five gives a summary and some conclusions.

An important part of this study is to identify key Singaporean institutes that perform research in the
three technology fields.

The selection process for identifying these key institutes and the descriptions of these key institutes
are given in the Appendices of this report. The selection of these key institutes was based on expert
opinions and an analysis of the patent applications and is described in appendix 1. Appendix 2 ranks
the institutes according to patents applied for. Appendix 3 contains descriptions of the patents
applied for per institute to give insight in the type of research performed at the institutes.

Appendix 4 contains the research profiles of the selected institutes based on the patent analysis as
well as information provided by A*STAR, the EDB and opinions by interviewed experts.
2. Background and Framework

2.1 Priority Medical Devices for the Netherlands, driven by care demand

2.1.1 The Health Care R&D Infrastructure in the Netherlands
In the Netherlands, all medical faculties and academic hospitals have been merged into University
Medical Centers (UMCs), concentrating health research in one place. Similarly ZON, which is the
research department of the public health authority, and MW-NWO, which is the health department
of the Netherlands Organization for Scientific Research, have been merged to form ZonMW. ZonMw
is now the Netherlands’ Organization for Health R&D (3).

ZonMW aims to improve health care by funding health care research and stimulating the translation
of this research so that innovation in health care can take place. The overall budget of ZonMw in
2009 was 600 million euro, receiving 75 % from the Ministry of Public Health Welfare & Sports and
25 % from the Netherlands Organization for Scientific Research, an organization under the ministry of
Education, Culture and Sciences.

Health research in the Netherlands is of high quality with a high productivity and high quality of
research papers in terms of citations and publications. However, governance and infrastructure of
health research are still quite dispersed.

2.1.2 Social Demand in the Netherlands: Capacity problem of an aging
Two demographic phenomena will have great impact on health care in the coming years in the
Netherlands. The first is aging of the post second world war baby boom generation. This year (2010)
the first baby boomers will turn 65 years of age. In the decades that follow, our already aging
population will age at an increased rate until, in 2040, 26 percent will be of age 65 and older. Result
will be a dramatic increase in the demand in health care, especially for the elderly and for chronic

The second phenomenon is the decline in birth rate that has taken place since the 1970s. By 2040,
the relative size of our working population will decrease from 61 percent in 2009 to 53 percent in
2040 (4). Our health care workers are already overburdened (5), yet the demand in health care will
increase while the relative work force will decrease. Our society simply does not have the manpower
to provide this care in the future unless we find a way to have more work done better by less people.
Although the numbers differ, ageing societies and the implications on their health care systems is a
worldwide phenomenon (6).

We can only realize humane health care delivery when patients become more autonomous and
professional care increases in efficiency dramatically. Therefore, system changes in health care are
needed that 1) increase the self care potential of the population with more responibility for the
patient, family and community, 2) make shifts possible from hospital care to home care and 3)
increase the labor productivity of professional health workers. To facilitate these system changes,
innovative technology needs to be developed.
2.1.3 IMDI.NL: Building on Existing Strengths in Strategic Areas

The Innovative Medical Devices Initiative NL (IMDI.NL) program is aimed at bringing mass and focus
on strategic areas of interest, building on existing, but dispersed, strengths in the Netherlands. Based
on the needs of society and existing research excellence, technological clusters have been defined
that will facilitate the development of such devices and that make optimal use of Dutch research
excellence in the medical device field, these are:

    1. Minimally invasive technology
    2. Medical Imaging
    3. Extramural Care

Minimally invasive technology: The means and methods used to minimize unnecessary damage of
healthy tissue that occurs during invasive diagnostics and treatment. Endoscopy and the use of
catheters for treatment or diagnostics are examples of minimal invasive techniques. A less invasive
intervention reduces risk of infection and the occurrence of complications. Minimally invasive
technology has the potential to increase health care efficiency mainly by reducing recovery time and
thus reducing the costly hospital stays and aftercare costs.

Medical Imaging: Medical imaging consists of the acquisition of images on one side and the
processing of these images on the other. Image acquisition includes technologies such as MRI, and
CT but also optical and acoustical techniques. Medical image processing is concerned with processing
the images acquired so that the end-user is able to better assess the images or that even a
quantitative analysis is possible. Visualization, Computer Aided Diagnosis (CAD) systems, multimodal
and molecular imaging are examples of this technique. Image processing software adds significant
value to existing technology without the need for the huge investments often required for imaging
hardware. Also, it has the potential to provide for improved and earlier diagnosis allowing efficient
intervention at an earlier stage.

Extramural Care: In the Netherlands, extramural care describes the extensive care for patients that
have not been taken up in an institution, where intramural care takes place. Aim is to develop
technology that allows care to take place at the patient’s home, preventing or delaying the transfer
of the patient to an intramural environment. Examples of diagnostic devices are devices for l ong
distance monitoring of vital signs but also small and portable point of care devices that can be used
to quickly screen for biological markers on site. Therapeutic devices include training devices for
rehabilitation. Other devices include prosthetics and devices aimed at increasing the quality of life
and self reliance of patients.

Eight Core Institutes

Under the IMDI.NL program eight candidate Core institutes have been selected in which the medical
and technical academic partners collaborate with industry to develop a new generation of medical
devices that will provide for the demand in health care, and boost our economy. Through these
centers, the Netherlands can bring mass and focus on areas of existing research excellence in order
to set global standards in these fields.
Figure 1. The eight candidate IMDI.NL Cor e Institutes. Taken from a presentation on the IMDI.NL theme 2010
2.2 Singapore Biotechnology: increasing economic competitiveness

2.2.1 R&D Infrastructure
Two government agencies both under the Ministry of Trade & Industry are responsible for
developing Singapore’s medical technology R&D infrastructure: the Agency for Science, Technology
and Research (A*Star) and the Economic Development Board (EDB) (7). Singapore’s medical
technology efforts are part of a greater effort aimed at making Singapore the Bioscience hub of Asia.
The National Medical Research Council (NMRC) under the ministry of health (MOH) plays a relatively
smaller role but is more and more involved in funding and supporting medical device research.

 A*STAR is the lead government agency dedicated to fostering scientific research and talent for a
knowledge-based economy. A*STAR currently oversees 14 research institutes and seven consortia &
centres and supports extramural research with the universities, hospital research centres, and other
local and international partners. A*STAR’s Biomedical Research Council (BMRC) nurtures public
sector research and development in biomedical sciences, A*STAR’s Science and Engineering Research
Council (SERC) in physical sciences & engineering. A Joint Council serves as a bridge between the two

The EDB is the lead government agency responsible for planning and executing strategies to enhance
Singapore’s position as a global business centre and grow the Singapore economy. It aims to do this
by attracting foreign investments, growing industry verticals and enhancing the Singaporean business
environment (9).

Governance and research are highly coordinated and centralized. Centralization goes as far as
creating physical hubs for biosciences research and science & engineering research in Biopolis and
Fusionopolis respectively. However, the decision to create a bioscience hub was not based on
existing capabilities present in Singapore, therefore, research activities outside the government
programmes are limited.

Singapore has a strong government that has great control over the course of research activities by
directing resources to strategic areas of importance. This results in a strong focus on and progress in
the fields destined as strategically important but limited developments outside these fields.
Researchers face the choice of sticking to their field with limited funding or follow current
government research goal making it difficult to develop core competencies in an area.

2.2.2 Economic Incentive: Diversification
The decision to create a biotechnology cluster had an economic and not social incentive and was part
of the government’s diversification strategy to become less dependent on IT. In 2000 they
announced their plans to become the bioscience hub of Asia and launched their Bioscience Initiative.
Singapore’s recent medical technology efforts are part of the Bioscience Initiative. Biotechnology was
to be the fourth pillar of the Singaporean economy, the other three being electronics, chemicals and
engineering (10).

Singapore’s economy, and with it its R&D infrastructure, has always been strongly directed by the
government. As early as the 1960s the government focused on building its manufacturing sector,
later efforts focused on its electronics industry.
Building clusters has been a policy for several years and Singapore has done so successfully in the
past for example for its electronics manufacturing cluster. However, different that Singapore’s other
pillars, the biotechnology field is strongly depended on the translation of scientific research to
innovative solutions. The enormous amount of research developments are too much for any
corporation to develop in-house and succesful transfer of knowledge between institutes becomes
more important (11).

Acknowledging this need, the Singaporean government announced to create a knowledge economy,
made clear in their 2003 statement:

Singapore wants to become a knowledge economy powered by innovation, creativity and
entrepreneurship. Not only technical skills and knowledge, but also the spirit of entrepreneurship
and creativity.

2.2.3 Bioscience Initiative: a big push approach
Starting with virtually no existing ecosystem, Singapore’s big push to create a BMS cluster started in
2000. Medical devices are one of the aims of the larger Bioscience Initiative, which distinguishes itself
from earlier cluster plans in its attempt to concurrently establish the entire value chain of a
biotechnology cluster, rather than focusing on one segment at a time. Before this time, medical
device R&D was already being done at the universities (NTU and NUS) but never at a large scale.

Government policy is executed with military precisioni, efficient and very much goal oriented by the
EDB and A*STAR. The EDB is responsible for bringing in investments and generating long term
economic value for Singapore. Bio*One Capital is the investment arm of the EDB and currently
manages over US$ 790 million in the therapeutics, services, medical technology and health care
fields. Attracting direct foreign investments (DFIs) from multinational corporations (MNCs) has been
an important economic strategy for Singapore throughout its history. EDB has focused on:

          Attracting medical device MNCs

          Nurturing Venture capital & promoting dedicated biotechnology firms & biomedical device

A*Star is responsible for putting in place policies, resources and research and education architecture
to build up Singapore’s research competencies. A*Star’s Biomedical Research Council (BMRC) is
responsible for building up the biomedical sciences, while the Science and Engineering Research
Council (SERC) is focused on building science and engineering capabilities. A joint council under
BMRC and SERC is responsible for medical engineering R&D activities. In recent years they have:

          Established public R&D institutes in Biomedical Sciences

          Developed an integrated physical infrastructure to house the BMS research cluster in
           Biopolis and the science and engineering research cluster in Fusionopolis.

    Chairman of A*Star lieutenant general Lim Chuan Poh was the former head of the Singaporean Armed Forces,
chairman of the EDB Mr. Leo Yip held a high position with Singaporean Police
       Attracted foreign talents and are developing young local talents

Newer goals were:

       Expanding clinical research capabilities in health care services sector

       Promoting translational research

The bioscience cluster has been developed in two phases. The first phase of development (2000-
2005) focused on establishing a firm foundation of basic biomedical research in Singapore to support
four key bioscience sectors: pharmaceuticals, biotechnology, medical technology and healthcare
services. To do this, five public BMRC research institutes developed core public research capabilities
in the areas of bioprocessing, chemical synthesis, genomics and proteomics, molecular and cell
biology, bioengineering and nanotechnology, and computational biology.

The second phase of development (2006-2010) focuses on strengthening capabilities in translational
and clinical research, while continuing to build up basic research capabilities. The BMRC established
institutes involved with clinical research and launched consortia initiatives that emphasize
translational research in areas such as cancer, bioimaging and stem cells.

The A*STAR Joint Council (A*JC) was formed in phase 2 in late 2007 to promote and strategically
support interdisciplinary research programs that span the fields of biomedical sciences and physical
sciences & engineering. A*STAR’s Strategic Initiatives in Medical Technology are coordinated by the
A*JC and resulted in more specific efforts oriented towards the medical device field.

Since 1996 Singapore has formulated its R&D commitment in strategic 5 year Science & Technology
plans. The next plan (2011-2015) already has been dubbed “the science, technology and enterprise
plan” suggesting a larger emphasis on the valorization of knowledge.
3. Singapore’s medical technology cluster

3.1 General
The Bioscience Initiative has resulted in a significant increase in R&D activity in the biomedical
sciences field also there have been increases in the biomedical engineering field.

Both the R&D expenditures and the number of researchers active in the fields have greatly increased.
In 2001, R&D expenditures in the biomedical sciences counted S$ 297.74 million, 2075 researchers
were working in the field. By 2008, R&D expenditures were S$ 1.06 billion and the number of
researchers had increased to 4099 researchers (12).

The biomedical engineering field is much smaller but has nevertheless seen a large growth in the
number of researchers and R&D expenditures as well. In 2001, only 43 researchers were involved in
biomedical engineering research, the total R&D expenditures were S$ 12.96 million. In 2008, these
numbers were 486 researchers and S$ 81.31 million.

Next follows a brief overview of the public and private research institutes that are active in the
medical device field. Most prominently active and well funded are A*STAR’s PRIs, however, their
activities in the medical device field are a phenomenon of the last few years only. More mature is
the research done at the universities NUS and NTU mainly in the medical imaging field although
minimally invasive robotic surgery is also an important subject at NTU. Similar as A*STAR’s PRIs, most
MNCs involved in medical device R&D are based in Singapore through the governments recent
efforts. Most have been attracted by the EDB in recent years. Furthermore, there are a few
successful homegrown start-ups, born with the support of government agencies such as SPRING
Singapore and Bio*One Capital.

3.2 Institutes
A*STAR’s Public Research Institutes

In the last ten years, A*STAR has set-up public research institutes to support its bioscience ambitions
(under BMRC) and its science and engineering strategic thrusts (under SERC) as shown in figure 1.
From 2003, many of these institutes have been housed in Biopolis and Fusionopolis respectively. Of
all IP generated by Singapore’s public infrastructure/funding 70 % is generated by A*STAR.
Fig. 1 Source: A*STAR, BMRC presentation to the Netherlands Embassy (13)

Most of the BMRC institutes are relatively new and have been established under the Bioscience
Initiative between 2000 and 2005. Although primarily aimed at fundamental biological research and
pharmaceuticals, some institutes and consortia under BMRC produce relevant contributions to the
medical device field. These include, the Institute of Bioengineering and Nanotechnology (IBN) and
the Singapore Bioimaging Consortium (SBIC). The IBN for example, developed the DropArrayTM
which provides a platform for miniaturized bioassays to analyze components solved in water. The
Biomedical Imaging Lab of the SBIC concentrated on neuroimaging and their brain atlas is being used

Most SERC institutes existed before the bioscience initiative and were formed to support Singapore ’s
electronics and IT industries. Recently, since the start of the MedTech Initiative in 2007-2008, the
SERC institutes are encouraged to focus more on working on innovations for the medical device field ,
an area of strategic importance to Singapore.

The Institute of Microelectronics (IME) for example, was set up in 1991 to support Singapore’s
semiconductor industry. It has built up expertise in wireless and sensor design and miniaturization by
its history of partnering with companies to develop a variety of products in these fields. In coherence
with their expertise, focus in the medical field is on point of care diagnostics, sensors for extra-mural
monitoring, and more generally miniaturization of medical devices.

The Institute for Infocomm Research (I²R) originally focused at supplying the IT industry with IP and
human capital now has an extensive program aimed at healthcare. Important topics include care for
the elderly, rehabilitation of stroke and intelligent medical imaging.
The Institute of Materials Research and Engineering (IMRE) has received investments from Sumitomo
Corporation to improve its microneedle design. Microneedles only penetrate the top layer of the skin
and provide a quick, painless and easy way to deliver medicine.


Singapore has three universities, two of which are involved in medical device R&D (the third,
Singapore’s Management University, is mainly aimed at managing). Research at the universities in
the imaging field is in a more mature state compared to the newly formed A*STAR institutes. At
Nanyang, some interesting minimally invasive research is performed.

The National University of Singapore (NUS) is with more than 1900 faculty and an endowment of
S$ 1.4 billion Singapore’s largest university. Together with A*STAR’s IME and IBN it has applied for
patents on microfluidics. Partnerships with the SBIC have led to patent applications in the medical
imaging field.

The National University Health System (NUHS) is Singapore’s main academic medical center and was
formed in 2008 by merging the National University Hospital (NUH) with the NUS’ School of Medicine
and Faculty of Dentistry. The department of surgery is home to MERCI, a platform to support medical
device innovation. Focus area is on niche markets that are feasible for small companies to innovate in,
subjects include devices for diabetes, flow sensors for stents, and pressure-sensing guidewires.

Relevant research the Nanyang Technological University (NTU) is done in the minimally invasive,
medical imaging as well as rehabilitation fields. Both their minimally invasive research, as well as
their rehabilitation research is being done from a robotics perspective. Imaging research takes place
at the School of Electrical & Electronic Engineering and in the Digital Media Technology Programme,
with important topics on functional imaging of cancer microcirculation and endomicroscopy
respectively. Patents applied for by NTU researchers vary from patents on endoscopic surgical robot
systems to high intensity focused ultrasound therapy for cancer and even microfluidic devices.


EDB’s attraction policy has contributed to the presence of more than 30 medical technology MNCs in
Singapore. In 2009, Singapore’s medical technology industry contributed about US$2 billion (S$ 3
billion) in manufacturing output and more than 8,000 jobs (14).

At first the EDB was mainly successful in attracting manufacturing facilities and corporate
headquarters but more recently also R&D facilities can be found in Singapore. Especially MNCs
involved with developing diagnostics devices are setting up base in Singapore.

For example, medical device MNCs that set up R&D facilities in Singapore include Fluidigm, Hill-Rom,
Qiagen and Perkin Elmer. Fluidigm and Hill-Rom set up their first Asian R&D facility for research
instrumentation and electronic systems in hospital beds respectively. Qiagen opened a molecular
diagnostics R&D centre in Singapore in partnership with Bio*One Capital, the investment arm of the
EDB. PerkinElmer opened its Centre of Excellence that will serve as the base for its R&D in research
instruments and diagnostics for Asia.
Becton Dickinson is an American medical technology company its Singapore based facility focuses on
minimally invasive devices such as needles and syringes, intravenous catheters, safety-engineered
and auto-disable devices. In recent years, its Singaporean facility has applied for several patents in
the minimally invasive field, including a flashback blood collection needle, a catheter having a low
drag septum and a roller wheel assisted guidewire advancer.

Biosensors is an American company that focuses on products for interventional cardiology. Their
R&D efforts in Singapore have resulted in patent applications on devices to determine the length and
size of stents and for test of passage for direct stenting. Welch Allyn, is developing portable devices
to monitor vital signs in its Singapore base. The appendix of this report contains the profiles of key
companies that are involved in R&D in the relevant fields.

Start-ups, spin-offs, local companies

Although, Singapore is not known to have an entrepreneurial culture and infrastructure to foster the
development of medical technology start-ups, there have been a few start-ups in the minimal
invasive, medical imaging, and extramural monitoring fields.

Amaranth Medical is a spin-off from NTU based on its biodegradable stent technology. The
technology was developed by the group of Subbu Venkatraman, the spin-off was formed to develop
and test a fully biodegradable stent technology.

Volume Interactions was a spin-off from A*STAR’s I2R and develops technology for 3D visualization
of medical images. The company has been taken over by Bracco and now continues under the name
of Bracco Advanced Medical Technologies.

HealthStats develops wearable blood pressure measurement devices. The device is the size of a
wristwatch and can measure central aortic pressure for as long as 24 hours continuously. HealthStats
received support from SPRING Singapore and International Enterprise, two government agencies
focused at entrepreneurship and internationalization of Singaporean companies respectively.

Test beds for novel devices

Several initiatives are aimed at partnering foreign MNCs with health care institutions to provide a
test-bed for new technology.

Intel has partnered Changi General Hospital to develop its Mobile Clinical Assistant, a lightweight
mobile device that provides information on patients’ conditions and test results to caregivers who
are on the move.

Hill-Rom, a company that makes hospital beds, has selected Singapore as the site for its Asia-Pacific
Innovation Center. The center will become the home base for new Hill -Rom teams focused on
research & development (R&D) projects for global applications and will become a center of
excellence for microelectronics and embedded software products.

Khoo Teck Puat Hospital (KTPH), preciously the Alexandra, has a reputation to be the best at geriatric
care in Singapore. They served as a model hospital for new technologies and have incorporated
smart beds and a new trolley that minimizes the need for nurses to get supplies from a central
station. Next year they test bed a Personal Health Record to link general practitioners with the
hospital with

The Singapore Ministry of Health has signed a contract with Accenture to implement the National
Electronic Health Record (NEHR) system, a key enabler of Singapore’s vision toward a national,
integrated health care system. The initial system release is scheduled for April 2011.
4. Translation of research into innovative medical devices

4.1 Medical device innovation
4.1.1 The normal process (Silicon Valley, Boston)

Even in experienced innovating countries as the US and the UK, medical device innovation is a
challenging venture. In these countries, typically IP either from either a university or the inspiration
of an entrepreneur forms the basis for a small start-up firm that tries to develop a new medical
technology. Their biggest challenge is to develop the technology past the proof-of-concept stage into
a more mature stage so that it becomes commercially interesting for VCs, larger corporations or
other private financers to fund (15).

Developing a new technology requires an entrepreneurial spirit and a willingness to take the risk. In
the US and UK, there exists such an entrepreneurial culture where many are willing to try and it is
accepted that also many will fail.

Another important factor for this kind of innovation model is the presence of a supporting
infrastructure to support the efforts of the small companies. Small companies typically do not have
all the skills and resources needed in house. Besides investors, an ecosystem of IP lawyers, regulatory
experts and experienced business men add to the skills and knowledge required to successfully
introduce a new technology to the market.

In its attempt to concurrently develop the entire value chain, Singapore faces the challenge of not
only attracting investors and developing a supportive infrastructure, also mechanisms should be
favorable for an entrepreneurial spirit that stimulates inventors to go the extra mile to take their
ideas to a commercially viable stage.

4.1.2 Challenges Singapore

Creating a biotechnology cluster including a medical device sector is quite a challenge. The
Singaporean government has achieved a lot building the infrastructure described in the previous
chapter, yet the largest challenge that remains is perhaps overcoming the lack of entrepreneurial
expertise in the island state.

Outside the infrastructure created by government programs, there is little expertise for small
innovators to support on. Furthermore, within the government programs there are still some
problems that may inhibit innovation. One is the lack of incentive for researchers at PRIs to pursue
entrepreneurial activities. Generally, these researchers are comfortably funded and are judged on
Key Performance Indicators (KPIs) that stimulate publication rather than innovation. Also, IP at
A*STAR is centralized under ExploitTech, leaving inadequate reward for individual researchers to
invest the substantial time and energy required to pursue commercialization of a new technology. In
the US, the Bayh Dole Act from 1982, allowing researchers to benefit from research results obtained
with public funding has been often mentioned as a cause for the innovative ness at academic level.

Another problem may be the lack of an entrepreneurial culture of risk taking. There is a lack of
knowledgeable VC companies with expertise in the medical device field that understand the risks and
benefits involved. The only real dedicated VC is perhaps Bio*One Capital, the investment arm of the
EDB, which is again a government institution.

4.2 Innovation programs
However, it is recognized that the process of innovation is a specialized challenge, requiring a special
effort. The A*STAR MedTech Initiative (A*MTIn) is an initiative managed by the Joint Council of
A*STAR whose aim is to help transform Singapore to be the leading generator of medical technology
innovators and innovations in Asia.

Under the initiative, collaborations with renowned institutions have been established that specifically
focus on the challenges of medical device innovation. These are the A*STAR – CIMIT collaboration
and the Singapore-Stanford Biodesign Program (SSB). Also, the Biomedical Engineering Program
(BEP) is focused on developing new technology based on clinician needs. As bridging funding gaps at
crucial stages is one of the main challenges faced by innovators, the TECS program aims to provide
means to fill these gaps.

A*STAR – CIMIT collaboration

The Center for Integration of Medicine and Innovative Technology (CIMIT) is a consortium of 11
institutions in the Boston area. Led by MGH Harvard, it consists mainly of hospitals and medical
centers. CIMIT was created to overcome the challenges faced by the innovators at its member
institutions. Central to its approach is to facilitate collaborations among clinicians, scientists and
engineers to develop innovative medical technologies and to provide limited early-stage funding at
key points of need (e.g. for prototype development) (16).

Three aims of the A*STAR – CIMIT collaboration are:

    1. To enable A*STAR to adopt CIMIT best practices in multidisciplinary research in medical
       device and clinical system applications

    2. To accelerate the implementation of technology developed by CIMIT in Boston. This concerns
       projects that are in the CIMIT pipeline. Singapore based resources will be used to accelerate
       implementation of this technology.

    3. To initiate Joint Grant Calls to encourage cross-continent collaborations of clinicians and
       engineers and to enhance capabilities, expertise and IP in MedTech innovations.

Singapore-Stanford Biodesign Program

The Stanford Biodesign Program is an educational program to train innovators in biomedical
engineering. It is one of the most well-known programs aimed specifically at developing the
discipline of medical device innovation.

The objective of the SSB is to train the next generation of Asian MedTech Innovators in Asia. The
program is centered around a fellowship in which a multi-disciplinary team is trained in the Biodesign
Innovation Process (17):

    1. Finding clinical needs and screening them
      2. Concept generation and selection

      3. Commercialization strategy and plan

Biomedical Engineering Program (BEP)

BEP is a programme aimed at developing technology driven by the needs identified by clinicians.
Currently, eight projects are clinician-engineer collaborations that develop medical devices and
solutions to improve patient care and cost-efficiency of the health care system (18). See below for an
overview of current BEP research programs.

S/N    Proposal                                              Medical Area     Technical     Clinical
                                                                              Institution   Collaborator

1      AGLAI A: Automatic GLaucoma Diagnosis and Its                          I2R           SERI
       Genetic Association Study through Medical Image       Ophthalmology

2      ArtsBCI: Advanced rehabilitation therapy for stroke   Neurology        I2R           TTSH NNI SGH
       based on Brain-Computer Interface                                                    NUS

3      Development of a Biosensor Prosthetic Vascular        Cardiovascular   IME           NUHS (Dept of
       Graft                                                                                Surgery)

4      Pressure Sensor Steerable Endovascular Catheter       Cardiovascular   IME           NUHS (Dept of

5      ISyNCC:- Intelligent System for Neuro Critical Care   Neurology        I2R           NNI

6      SEIZE : Automated video-EEG analytic system in        Neurology        I2R           KKH
       seizure detection in the Epilepsy Monitoring Unit

7      IRAS: Image-Guided Robot Assisted Surgical Training   General          I2R           NUHS (Dept of
                                                             Surgery                        Surgery)

8      Developing a quantitative computational approach      Cardiovascular   IHPC          NHC
       for comprehensive assessment of left ventricular
       remodelling after myocardial infarction

SERI: Singapore Eye Research Institute

TTSH: Tan Tock Seng Hospital

NNI: National Neuroscience Institute

SGH: Singapore General Hospital

NUHS: National University Health System

KKH: KK Hospital
NHC: National Heart Center

Technology Enterprise Commercialization Scheme (TECS)

SPRING Singapore, is Singapore’s main agency under the Ministry of Trade and Industry for
enterprise development. The TECS is a S$ 75 million scheme to provide technology start-ups and
enterprising public-sector researchers with competitive, early-stage funding for Proof-of-concept
(POC) or proof-of-value projects (POV).

POC projects are aimed at ideas in the conceptualization stage and technical / scientific viability still
needs to be proven. Each POC project may receive a maximum of S$ 250,000. POV funds are aimed
at developing a working prototype or to validate the commercial merit of an established concept. Up
to 85% of qualifying costs for each project will be supported, subject to a maximum of S$500,000.
5. Conclusions
Starting from virtually no research infrastructure, the Singaporean government has established a
biotechnology cluster in ten years. Part of this cluster is Singapore’s medical technology sector.

The government has carefully researched and planned all the necessary steps to create the new
bioscience hub. And as important, they have put their money where their ambitions are and followed
through with long term support and dedication.

The first phase was part of the 2001-2005 Science & Technology Plan and aimed to build the
scientific foundations required for the knowledge intensive biotechnology infrastructure. A*STAR set
out to set up public research institutes, housed them in a physical hub (Biopolis), attracted world-
renowned top-talent to fill them and focused on educating local talent in the biosciences. The EDB
continued their successful strategy of attracting foreign MNCs, first mainly in manufacturing (as they
have always done) but later shifted focus to include the R&D part of the value chain.

Phase two (part of the 2006-2010 Science & Technology Plan) continued the same trends in building
the basic research foundations but also focused on building translational research capabilities. It was
in this period (2006-2010) that Singapore started an initiative specifically aimed at developing their
native medical device R&D capabilities through the MedTech Initiative.

Furthermore, the EDB and A*Star are continually looking at practical approaches on how to improve
the situation, starting new intitiatives and keeping dialogue open. All this is an exemplary effort in
creating the necessary infrastructure and it is admirable to see the efficiency in which the
Singaporean government works to improve the situation.

However, Singapore’s centrally planned medical technology cluster is not based on an existing
working ecosystem for innovation, and outside the government plan little alternatives exist. This
holds especially for medtech start ups, the crucial motor for innovation in renowned hubs in the US
and the UK. For example, Bio*One Capital is the only serious funding source and that is part of the

The lack of alternative pathways makes innovators in the medical technology field dependent on the
options provided by the government plan and a problem may arise when within the plan no s uficient
incentives exist to be entrepreneurial. Furthermore, extensive as the plan may be, it may be difficult
to centrally plan innovations, which by definition are unpredictable, and often the result from
unplanned serendipity and luck. Even in the US, the world’s largest medical technology innovator,
developing novel medical devices remains a huge challenge.

Yet, since the inception of the Bioscience Initiative Singapore has seen several successful start-ups
already and with the MedTech Initiative efforts aimed at medical device innovation are beginning to
take off. Singapore’s well established engineering research institutes are eager to apply knowledge
and skills to solve problems in for medical device field and now have a platform to do so.

Soon the 2011-2015 Science, Technology & Enterprise Plan will be presented and the adapted name
suggests more focus on (or at least acknowledges the need for) the crucial part of translating
knowledge to marketable solutions. Time will tell if Singapore is able to create the vibrant hub for
bioscience innovation it has set it sights on.
6. Acknowledgements

This study was possible with the help of many people. We would like to express our gratitude to all
representatives from research institutions, universities and companies who collaborated in this
project. The people interviewed are by no means responsible for any mistakes or misinterpretations
made by the author. Special thanks go to the NL Patent Office for their contribution to the patent
7. References

1. Website: www.IMDI.nl

2. Website MTI, Growing our economy: http://app.mti.gov.sg/default.asp?id=433

3. Presentation Gerrit van Ark: New Medical Devices for Aging Societies, Sino-Dutch R&D workshop,
Shanghai 17 – 19 August 2010

4. VTV-2006 Kernboodschappen: Door vergrijzing in de toekomst meer en andere zorg nodig, RIVM,

5. Nationale Enquete: Werken in de Zorg, Menzis 2010

6. "UN Human Development Report 2005". United Nations Development Programme.

7. Website: Bioscience Initiative: http://www.a-

8. Website: A*STAR: http://www.a-star.edu.sg/

9. Website Economic Development Board (EDB): www.edb.gov.sg

10. Finegold D., Wong P.K. and Cheah T.C. “Adapting a foreign direct investment strategy to the
knowledge economy: The case of Singapore’s emerging biotechnology cluster”, European Planning
Studies, 12(7): 921-941 (2004)

11. Okamoto Y. ”Creating a Biotechnology Cluster: Lessons to learn from Singapore’s Experience”,
Doshisha Journal of Policy Studies Vol.3, (2009)

12. A*STAR, National Survey of R&D 2001 & 2008

13. Presentation BMRC to Dutch Embassy

14. EDB Facts & Figures:

15. Medical Device Development: From Prototype to Regulatory Approval,

16. CIMIT: A Prototype Structure for Accelerating the Clinical Impact of Research on Novel
Technologies, John A. Parrish, M.D. and Ronald S. Newbower, Ph. D.

17. Website Singapore-Stanford Biodesign: http://biodesign.stanford.edu/bdn/singapore/index.jsp

18. Medtech Presentation for the Netherlands Embassy

A1 The patent analysis
The patent analysis was performed together with the NL Patent Office and resulted in lists that rank
the most productive institutes in terms of patent applications in each technology cluster. The patent
analysis focuses on patent applications, applied for in the period 2000-2009. Patents applied for in
this period that were published after week 24 of 2010 (query date) are not part of this analysis.
Singaporean organizations or foreign organizations that perform research in Singapore are
documented by patent offices as Singaporean applicants or Singaporean inventors and are
incorporated in this study.

The results were selected from the US Patent and Trademark Office (USPTO), the European Patent
Office (EPO) and the World Intellectual Property Organization (WIPO) databases using ECLA-codes
(Table A1). The European Classification system (ECLA) is used for carrying out patent application
searches and is built on top of the International Patent Classification system (IPC). ECLA contains
approximately twice as many entries as the IPC (133000 vs. 71000), and ECLA symbols are allocated
by qualified EPO examiners to documents falling in their field of expertise. Therefore a higher
precision in the definition of the scope a specific entry, and a higher precision when searching with
ECLA symbols rather than with IPC ones is expected. The other side of the medal is that documents
that are not available in one of the official EPO languages (English, German or French) are not
accessible via ECLA.

Table A1. ECLA Codes used in Queries

Minimally invasive techniques         (A61B17/00E or A61B17/02E or A61B17/04E or A61B17/12L2 or
                                      A61B17/128E or A61B17/32E or A61B1 or A61M25 or
                                      G09B23/28E or G09B23/28E)/ic/ec

Medical optics & acoustics            (A61B8 or A61B5/00P+ or A61B19/00N2 or A61N7)/ic/ec

Medical image processing              (G06F19/00M5I or G06T7/00B2 or G06T17/40 or A61B5/055 or
                                      G06T11/00T or A61B8 or ((G06T7/00D or G06T7/00S) and
                                      (medical+ or cardio+ or surg+ or diagnos+ or endoscop+ or
                                      bronchoscop+ or gastroscop+ or colonscop+ or laparoscop+ or
                                      thoracoscop+ or arthroscop+)/ti/ab))/ic/ec

High precision instrumentation        (B01L3/00C6M or A61B5/0476)/ic/ec

Extramural care                       (G06F19/00M3F/ic/ec) or (((G01N33/48 or G01N33/50 OR
                                      G01N33/52)/ic/ec) AND ((POINT 2W CARE) OR (HOME 2D
                                      DIAGNOS+))/TI/AB) OR ((H04L29/08N11/ic/ec) AND (HEALTH
                                      OR DISEASE IR DIAGNOS+ OR CARE OR MEDICIN+)/TI/AB) OR

The codes used attempt to cover as well as possible a wide variety of patent applications that fall
within the five original IMDI.NL technology clusters but by no means cover the entire field. Later
IMDI.NL chose to redefine these five clusters in three areas: minimally invasive technology remained,
optics & acoustics and image processing became medical imaging, high precision instrumentation are
incorporated in extramural care in the form of rehabilitation devices (neuro) and lab-on-a-chip
devices. It is also possible that less relevant applications have been included in the resulting list.
However, rather than trying to be an accurate account of every single patent applied for in the three
technology clusters, this study aims to get insight in the research productivity of key institutes.

Institute research profiles

Research profiles of the key research institutes contain a general information part and a part that
briefly describes some of the research interests of the institute. The general information part is
largely taken literally from wikipedia, but also other public internet sources such as wikinvest or
public websites have been used. Besides these sources, the descriptions of the institutes’ research
interests, are also derived from other sources including the institute websites and interviews with
representatives from universities, companies and research institutions.
A2 Patent Applications
Minimally Invasive Technology

Rnk   Applicant                 Country   Total   2000   2001   2002   2003   2004   2005   2006   2007   2008   Share

  1   AGENCY SCIENCE TECH &     SG           3                            1      2                               12.5%

  2   BECTON DICKINSON          SG, US       3              1             1                                  1   12.5%

  3   NANYANG TECHNOLOGICAL     SG           3                                   1             1      1          12.5%

  4   NAT UNIV OF SINGAPORE     SG           3                                   1      1      1                 12.5%

  5   BRACCO                    IT           2                            1                    1                  8.3%

  6   NAT UNIVERSITY HOSPITAL   SG           2                     1                                  1           8.3%

  7   PANG AH SAN               SG           2                                          1             1           8.3%

  8   BIOSENSORS INTERNAT PTE   SG           1              1                                                     4.2%

  9   INST INFOCOMM RES         SG           1                     1                                              4.2%

 10   JMS CO LTD                JP, SG       1                                   1                                4.2%

 11   KOREA INST OF SCIENCE     KR           1              1                                                     4.2%

 12   LENOVO CO                 SG           1                            1                                       4.2%

 13   MPORT PTE LTD             SG           1                                          1                         4.2%

 14   NANYANG POLYTECHNIC       SG           1                                                               1    4.2%

 15   SIEMENS GROUP             SG           1                                                               1    4.2%

 16   TEO KENG SIANG RICHARD    SG           1       1                                                            4.2%

 17   TRANSCATHETER             DE           1                                                               1    4.2%

 18   UNI JOHNS HOPKINS         US           1                     1                                              4.2%

 19   USGI MEDICAL INC          US           1                                          1                         4.2%

                                TOTAL       24
Medical Optics & Acoustics

Rnk   Applicant                 Country   Total   2000   2001   2002   2003   2004   2005   2006   2007   2008   Share

  1   UNI NANYANG               SG           5                     1             1             1      1      1   38.5%

  2   AGENCY SCIENCE TECH &     SG           1                                   1                                7.7%

  3   AVAGO TECHNOLOGIES        SG           1                                   1                                7.7%

  4   BC CANCER AGENCY          CA           1                            1                                       7.7%

  5   IMPERIAL COLLEGE LONDON   GB           1                            1                                       7.7%

  6   NAT UNIVERSITY HOSPITAL   SG           1                                                        1           7.7%

  7   NAT UNIVERSITY HOSPITAL   SG           1                                                        1           7.7%

  8   SINGAPORE HEALTH          SG           1                                                 1                  7.7%

  9   UNI JOHNS HOPKINS         US           1                                                               1    7.7%

 10   UNI PRINCETON             US           1                                          1                         7.7%

 11   UNI ROCHESTER             US           1                                                               1    7.7%

 12   UNI SINGAPORE             SG           1                                   1                                7.7%

 13   VOLUME INTERACTIONS PTE   SG           1                            1                                       7.7%

                                TOTAL       13

Medical Image Processing

Rnk   Applicant                 Country   Total   2000   2001   2002   2003   2004   2005   2006   2007   2008   Share

  1   AGENCY SCIENCE TECH &     SG          22                            5      3      6      4      1      3   40.0%

  2   BRACCO                    IT           9                            1      2      2      3      1          16.4%

  3   VOLUME INTERACTIONS PTE   SG           8       1      5      1      1                                      14.5%

  4   NANYANG TECHNOLOGICAL     SG           5                     1                           1      1      2    9.1%

  5   KENT RIDGE DIGITAL LABS   SG           2       2                                                            3.6%

  6   UNI JOHNS HOPKINS         US           2                     1                                         1    3.6%

  7   CHUI CHEE KONG            SG           1       1                                                            1.8%

  8   ELEMENT PTE LTD G         SG           1                                          1                         1.8%
  9   IMPERIAL COLLEGE LONDON   GB           1                            1                                       1.8%

 10   INST INFOCOMM RES         SG           1                     1                                              1.8%

 11   MATRIXVIEW LTD            SG           1                     1                                              1.8%

 12   NANYANG POLYTECHNIC       SG           1                            1                                       1.8%

 13   NAT NEUROSCIENCE INST     SG           1                            1                                       1.8%

 14   NAT UNIV OF SINGAPORE     SG           1                                   1                                1.8%

 15   NAT UNIVERSITY HOSPITAL   SG           1                                                        1           1.8%

 16   SINGAPORE HEALTH          SG           1                                                 1                  1.8%

 17   UNI CARNEGIE MELLON       US           1                                                 1                  1.8%

 18   UNI PRINCETON             US           1                                          1                         1.8%

 19   WEIKE S PTE LTD           SG           1                                                 1                  1.8%

                                TOTAL       55

High Precision Instrumentation

Rnk   Applicant                 Country   Total   2000   2001   2002   2003   2004   2005   2006   2007   2008   Share

  1   AGENCY SCIENCE TECH &     SG          14                            3      2      3      1      3      2   45.2%

  2   NAT UNIV OF SINGAPORE     SG           8              1             3             3                    1   25.8%

  3   NANYANG TECHNOLOGICAL     SG           5                                   4      1                        16.1%

  4   NANYANG POLYTECHNIC       SG           3                                                 3                  9.7%

  5   ATTOGENIX BIOSYSTEMS      SG           2                                          2                         6.5%
      PTE LTD

  6   DSO NAT LAB               SG           2              2                                                     6.5%

  7   NTU VENTURES PTE LTD      SG           2              2                                                     6.5%

  8   BURSTEIN TECHNOLOGIES     US           1                                   1                                3.2%

  9   CHAI CHEE KIONG JOHN      SG           1                                                 1                  3.2%

 10   HAMADI CHAREF BRAHIM      SG           1                                                               1    3.2%

 11   INST OF MENTAL HEALTH     SG           1                                                               1    3.2%

 12   INST OF                   SG           1              1                                                     3.2%

 13   KENT RIDGE DIGITAL LABS   SG           1              1                                                     3.2%
 14   NAGACO & CO LTD          JP           1                                   1                                3.2%

 15   NGUYEN NAM TRUNG         SG           1                                                 1                  3.2%

 16   TING TECK HUI            SG           1                                                 1                  3.2%

 17   WANG CHENG               SG           1                                                 1                  3.2%

 18   WONG TECK NENG           SG           1                                                 1                  3.2%

 19   YAP YIT FATT             SG           1                                                 1                  3.2%

                               TOTAL       31                                                                   100.0

Extramural Care

Rnk   Applicant                Country   Total   2000   2001   2002   2003   2004   2005   2006   2007   2008   Share

  1   HOARTON LLOYD DOUGLAS    GB           1                     1                                             33.3%

  2   IBA HEALTH LTD           AU           1                                   1                               33.3%

  3   MSC HEALTHCARE PTE LTD   SG           1                     1                                             33.3%

                               TOTAAL       3
A3 Patent Descriptions per Institute

Inventors                          Patent Application
AGARWAL AJAY [SG],BALASUBRAMANIAN  Transparent microfluidic device
LEVENT YOBAS [SG],CHEOW LIH FENG [SG]    Fluid cartridge, pump and fluid valve arrangement

Inventors                          Patent Application
GUAN CUNTAI [SG],ZHANG HAIHONG     A system and method for processing brain signals in a bci system
HOU ZUJUN [SG],HUANG SU [SG]             Method and device for correction of magnetic resonance images

Inventors                         Patent Application
DUMOND JARRETT [SG],LOW HONG Y    Imprint lithographic method for making a polymeric structure

Inventors                         Patent Application
LIU TONG [SG]                     Computed tomography method and apparatus for centre-of-rotation

Inventors                               Patent Application
ILIESCU CIPRIAN [SG],XU GUOLIN [SG],TAY Biochip for sorting and lysing biological samples
LEE KI BANG [SG],HSIEH TSENG-MING [SG]   Configurable microfluidic device and method
YU HANRY [SG],TOH YI-CHIN [SG],NG SAN    Cell culture device

Inventors                           Patent Application
AGARWAL AJAY [SG],BALASUBRAMANIAN   Transparent microfluidic device
BHANU PARKASH K N [SG],GUPTA VARSHA      Segmenting infarct in diffusion-weighted imaging volume
GUPTA VARSHA [SG],PRAKASH BHANU K N      Method for identifying a pathological region of a scan, such as an
                                         ischemic stroke region of an mri scan
HU QINGMAO [SG]                          Segmenting infarcts from diffusion-weighted images
HU QINGMAO [SG],AZIZ AAMER               Method and apparatus for extracting third ventricle information
HU QINGMAO [SG],HOU ZUJUN                Methods and apparatus for binarising images
HU QINGMAO [SG],NOWINSKI WIESLAW         Automated method for identifying landmarks within an image of the
HU QINGMAO [SG],NOWINSKI WIESLAW         Method, apparatus and computer software for segmenting the brain
                                         from mr data
HU QINGMAO [SG],NOWINSKI WIESLAW         Brain image segmentation from ct data
HUANG SU [SG],NOWINSKI WIESLAW               Method and apparatus for editing three-dimensional images
K N BHANU P [SG],VOLKAU IHAR                 Locating a mid-sagittal plane
LIU JIMIN [SG],HUANG SU [SG],NOWINSKI        Method and apparatus for registration of a n atlas to an image
LIU JIMIN [SG],HUANG SU [SG],NOWINSKI        A method and system for anatomy structure segmentation and
                                             modeling in an image
MA XIN [SG]                                  Method and apparatus for measuring motion of a body in a number of
NAGARAJA RAO BHANU P K [SG],NOWINSKI         Automatic identification of the anterior and posterior commissure
NOWINSKI WIESLAW L [SG]                      Detection and localization of vascular occlusion from angiography data
NOWINSKI WIESLAW L [SG],BEAUCHAMP            Superimposing brain atlas images and brain images with delineation of
                                             infarct and penumbra for stroke diagnosis
QIAO YU [SG],HU QINGMAO [SG],QIAN            Obtaining a threshold for partitioning a dataset based on class variance
                                             and contrast
VOLKAU IHAR [SG],NOWINSKI WIESLAW L          Method and apparatus for determining asymmetry in an image
ZHANG NAN [SG],KNOLL WOLFGANG                Sensor chip for use in optical spectroscopy

Inventors                         Patent Application
[SG],LIM CHOIE C T [SG],NARAYANASWAMI        Method and apparatus for building a multi -discipline and multi -media
BANUKUMAR [SG]                               personal medical image library

Inventors                              Patent Application
CHONG SER CHOONG [SG],XIE LING [SG],JI Microfluidics package and method of fabricating the same
JI HONGMIAO [SG],YOBAS LEVENT [SG],CHEN      Immobilization unit and device for isolation of nucleic acid molecules
KHATIB OUSSAMA [US],MA XIN                   Apparatus for medical and/or simulation procedures
PREMACHANDRAN CHIRAYARIKATHUVE               Microprobe for 3d bio-imaging, method for fabricating the same and
                                             use thereof
SAMPER VICTOR [SG],CONG LIN [SG],JI          Microfluidics chips and methods of using same
SAMPER VICTOR [SG],CONG LIN [SG],JI          Microfluidics packages and methods of using same
GUAN CUNTAI [SG],HAMADI CHAREF               Device and method for generating a representation of a subject's
                                             attention level
Inventors                          Patent Application
OVISO DOMINADOR FORTALEZA JR       Methods and device for transmitting, enclosing and analysing fluid
VERDE SANCHEZ DAVID [ES],THAM KUOK Method and apparatus for analysing a sample fluid

Inventors                                Patent Application
[CA],HUANG ZHIWEI [SG],MCLEAN DAVID I    Multimodal Detection Of Tissue Abnormalities Based On Raman And
[CA]                                     Background Fluorescence Spectroscopy

Inventors                         Patent Application
ALVIN TAN CHEE LEONG [SG],JON MOH Flashback blood collection needle with needle shield
HEH KOK BOON [SG],WIDJAJA ANTON [SG]     Roller wheel assisted guidewire advancer
LEONG ALVIN TAN CHEE [SG]                Flashback blood collection needle
LEONG ALVIN TAN CHEE [SG]                Flashback blood collection needle
LEONG ALVIN TAN CHEE [SG]                Flashback blood collection needle
MENG CLEMENT WAN CHYE [SG],JIN CHENG     Catheter having a low drag septum
MENG CLEMENT WAN CHYE [SG],JIN CHENG     Catheter having a low drag septum
TAN CHEE LEONG [SG],MOH JON [SG],SIM     Flashback blood collection needle
TAN CHEE LEONG ALVIN [SG],MOH JON        Flashback blood collection needle

Inventors                                Patent Application
KOH SIAM SOON PHILIP [SG],PING YE        An apparatus and method for determining the length and size of stents
                                         to be deployed in a stenotic blood vessel and for test of passage for
WUI [SG]                                 direct stenting

Inventors                                Patent Application
AGUSANTO KUSUMA [SG],ZHU CHUANGGUI       Methods and apparatuses for stereoscopic image guided surgical
CHIA WEE KEE [SG]                        2d / 3d integrated contour editor
CHIA WEE KEE [SG],TAO CHEN [SG]          Systems and methods for generating and measuring surface lines on
                                         mesh surfaces and volume objects and mesh cutting techniques
                                         ("curved measurement")
CHUA GIM GUAN [SG],SERRA LUIS [SG],NG    Method of rendering a graphi cs image
CHUANGGUI ZHU [SG],AGUSANTO KUSUMA       Methods and apparati for surgical navigation and visualization with
                                         microscope ("micro dex-ray")
KOCKRO RALF ALFONS [SG]                  Computer enhanced surgical navigation imaging system (camera
LEE EUGENE C K [SG]                      Systems and methods for displaying multiple views of a single 3d
                                         rendering ("multiple views")
LEE JEROME CHAN [SG],GOH LIN CHIA        Apparatus and method for manipulating a three-dimensional
NG HERN [SG],GOH LIN CHIA [SG],WANG        Method and system for selective visualization and interaction with 3d
                                           image data
NG HERN [SG],GOH LIN CHIA [SG],WANG        Method and system for selective visualization and interaction with 3d
                                           image data, in a tunnel viewer
NG HERN [SG],SERRA LUIS [SG]               Methods and systems for interacting with a 3d visualization system
                                           using a 2d interface ("dextrolap")
SERRA DEL MOLINO LUIS [SG],GOH LIN CHIA    Systems and methods for collaborative interactive visualization of 3d
                                           data sets over a network ("dextronet")
SERRA LUIS [SG],CHOON CHUA B [SG]          System and method for three-dimensional space management and
                                           visualization of ultrasound data ("sonodex")
SERRA LUIS [SG],CHOON CHUA B [SG]          System and method for a virtual interface for ultrasound scanners
SERRA LUIS [SG],CHOON CHUA B [SG]          Methods and systems for creating 4d images using multiple 2d images
                                           acquired in real-time ("4d ultrasound")
SERRA LUIS [SG],CHOON CHUA B [SG]          System and method for three-dimensional space management and
                                           visualization of ultrasound data ("sonodex")
SERRA LUIS [SG],CHOON CHUA B [SG]          System and method for a virtual interface for ultrasound scanners
SERRA LUIS [SG],CHOON CHUA B [SG]          Methods and systems for creating 4d images using multiple 2d images
                                           acquired in real-time ("4d ultrasound")
SERRA LUIS [SG],WU YING HUI FREDDIE [SG]   System and methods for screening a luminal organ "lumen viewer" -
                                           system and methods for screening a luminal organ
SERRA LUIS [SG],WU YING HUI FREDDIE [SG]   System and methods for screening a luminal organ "lumen viewer" -
                                           system and methods for screening a luminal organ
WU YINGHUI FREDDIE [SG]                    Systems and methods to optimize volumetric rendering of a region of
                                           interest ("tension vectors") - system and method to optimize
                                           volumetric rendering of a region of interest
ZHOU LU P [AU],SERRA LUIS [SG],GOH LIN C   Systems and methods for collaborative interactive visualization of 3d
                                           data sets over a network ("dextronet")
ZHU CHUANGGUI [SG],LIANG XIAOHONG          Methods and apparatuses for registration in image guided surgery

Inventors                                  Patent Application
YEOW SHIN WE [SG],WOON TONG WING           System and apparatus for vicinity and i n-building visualization,
                                           planning, monitoring and exploring

Inventors                                  Patent Application
COHEN BRIAN [SG]                           System for customizing patient clinical data

Inventors                          Patent Application
RAGHAVAN RAGHU [US],POSTON TIMOTHY Apparatus, system and method for calibrating magnetic resonance
                                   receiver coils
RAGHAVAN RAGHU [US],VISWANATHAN    Drug delivery and catheter systems, apparatus and processes
RAGHAVAN RAGHU [US],VISWANATHAN            Drug delivery and catheter systems, apparatus and processes
RAGHAVAN RAGHU [US],POSTON TIMOTHY         Method for dynamic characterization of density fields in a compound

Inventors                                  Patent Application
TOUMAZOU CHRISTOPHER [GB],MCLEOD           Implantable Surface Acoustic Wave Devices for Long Term Clinical
TOUMAZOU CHRISTOPHER [GB],MCLEOD           Implantable Surface Acoustic Wave Devices for Long Term Clinical

Inventors                                  Patent Application
ZOU QUANBO [SG],SRIDHAR UPPILI             Miniaturized thermal cycler

Inventors                                  Patent Application
LIM KAH HOCK [SG],LOW BOON TONG            Winged medical needle device
YANG CHEK L [SG]                           Safeguard cap, injection needle with safeguard cap, and medical device
                                           with safeguard cap

Inventors                           Patent Application
[US],GOLAY XAVIER PH D [SG]                Microvascular blood volume magnetic resonance imaging

Inventors                                  Patent Application
NOWINSKI WIESLAW L [SG],BIALOU DZMITRY     Methods and apparatus for calculating and presenting the probabilistic
                                           functional maps of the human brain
NOWINSKI WIESLAW L                         Methods and apparatus for processing medical images
CHUI CHEE-KONG [SG],WEI HUA [SG],WANG      Virtual surgery system with force feedback

Inventors                             Patent Application
PHEE SOO JAY LOUIS [SG],ARENA ALBERTO Endoscopic Device For Locomotion Through The Gastro-Intestinal Tract

Inventors                         Patent Application
[SG],CHUI CHEE KONG [SG]                   Device for Laparoscopic or Thoracoscopic Surgery

Inventors                                  Patent Application
SOON TEONG [SG],TOH DA JUN [SG]            Health-care system

Inventors                          Patent Application
KIDO HORACIO [US],NORTON JAMES R   Fluidic circuits for sample preparation including bio-discs and methods
[US],COOMBS JAMES H [SG]                 relating thereto

Inventors                                Patent Application
CHING WEE SOON [SG]                      Method and system for automatic vision inspection and classification of
                                         microarray slides
ONG ENG HOO TEDDY [SG],PRABHU            Lab-on-cd systems with magnetically actuated micro check valves
                                         and/or magnetic immobilization
PRABHU VINAYAK ASHOK [SG],ONG HUI YNG    Micro thermal cycler with selective heat isolation
PRABHU VINAYAK ASHOK [SG],ONG HUI YNG    Smart nano-integrated system assembly
TAN SENG SING [SG],NG CHIN TIONG [SG]    Process and apparatus for determining blood flow rate or cardiac

Inventors                           Patent application
CHAUHAN SUNITA [SG]                 Mechanical manipulator for hifu transducers
CHAUHAN SUNITA [SG]                 Mechanical manipulator for hifu transducers
CHAUHAN SUNITA [SG],MISHRA RANJAN K Apparatus and method for removing abnormal tissue
CHAUHAN SUNITA [SG],MISHRA RANJAN K      Apparatus and method for removing abnormal tissue
CHAUHAN SUNITA [SG],NG WAN SING [SG]     Ultrasonic treatment of breast cancer
CHAUHAN SUNITA [SG],NG WAN SING [SG]     Ultrasonic treatment of breast cancer
LI CHANGMING [SG]                        Microchip and method for detecting molecules and mol ecular
LI CHANGMING [SG]                        Addressable chem/bio chip array
LI CHANGMING [SG]                        Microchip and method for detecting molecules and molecular
LIU AI QUN [SG],LIANG XIAO JUN           Microfluidic cell sorter system
MA JAN [SG],LOW ADRIAN FATT HOE          Micro-emulsifier for arterial thrombus removal
MA JAN [SG],LOW FATT HOE ADRIAN          Micro-emulsifier for arterial thrombus removal
MA JAN [SG],LOW FATT HOE ADRIAN          Micro-emulsifier for arterial thrombus removal
NGUYEN NAM TRUNG [SG],LASSEMONO          Microfluidic sensor for interfacial tension measurement and method
                                         for measuring interfacial tension
WONG TECK NENG [SG],NGUYEN NAM           Method and apparatus for controlling multi -fluid flow in a micro

Inventors                         Patent Application
BATES RODERICK WAYLAND [SG],GOLAY Intravascular contrast agents

Inventors                       Patent Application
YU [SG],CHUNG SHEUNG CHEE [CN]            Surgical robotic system for flexible endoscopy

Inventors                           Patent Application
TSANG BIH SHIOU CHARLES [SG],NG WAN Method and apparatus for anorectal examination
TSANG BIH SHIOU CHARLES [SG],NG WAN       Method and apparatus for anorectal examination
TSANG BIH SHIOU CHARLES [SG],NG WAN       Method and apparatus for anorectal examination

Inventors                             Patent Application
CHENG WAI SAM C [SG],NG WAN SING [SG] Apparatus and method for motorised placement of needle
CHENG WAI SAM C [SG],NG WAN SING [SG] Apparatus and method for motorised pla cement of needle

Inventors                                 Patent Application
LI XIAOPING [SG],QIAN XINBO [SG],NG WU    A system and method for monitoring mental fatigue
RAMALINGAM MURUGAN                        Production of nano-sized hydroxyapatite particles
SAMPER VICTOR [SG],HONGMIAO JI [SG],YU    Nucleic acid purification chip
T [SG]

Inventors                        Patent Application
RAMOS [SG],JONHENDRO [SG]                 An endoscopy treatment management system

Inventors                       Patent Application
[SG],TING TECK HUI [SG]                   Active control for droplet-based microfluidics

Inventors                            Patent Application
GONG HAIQING [SG],YAP PENG HUAT ERIC Method for detecting disease
YAP PENG HUAT ERIC [SG],GONG HAIQING      Sample preparation integrated chip - integrated fluidic device for
[SG],CHEN LONGQING [SG]                  sample preparation and assay

Inventors                         Patent Application
COLIN ANNIE [FR],CRISTOBAL GALDER Method and installation for determining rheological characteristics of a
                                  fluid, and corresponding identifying method

Inventors                                Patent Application
BAUER MICHAEL [DE],GOLLER BERND          Biosensor with smart card configuration
SUN YING [SG],GUHRING JENS [US],JOLLY    Automatic localization of the left ventricle in cardiac cine magnetic
                                         resonance imaging
SUN YING [SG],GUHRING JENS [US],SPEIER   Automatic deter mination of field of view in cardiac mri
RAMAMURTHY VENKAT RAGHAVAN               System and method for loading timepoints for analysis of disease
                                         progression or response to therapy

Inventors                            Patent Application
                                     Stent, which can be decreased in diameter again in a controlled
GOETZ WOLFGANG [DE],LIM HOU SEN [SG] manner from the expanded state

Inventors                                Patent Application
AHRENS ERIC T [US],SRINIVAS MANGALA      Cellular labeling and quantification for nuclear magnetic resonance
[SG]                                     techniques

Inventors                                Patent Application
MILLER MICHAEL I [US],MORI SUSUMU        Automated surface-based anatomical analysis based on atlas -based
                                         segmentation of medical imaging
MILLER MICHAEL I [US],MORI SUSUMU        Automated surface-based anatomical analysis based on atlas-based
                                         segmentation of medical imaging
SMITH SETH [US],GOLAY XAVIER [CH],ZIJL   Quantitative single image-based magnetization transfer weighted
                                         imaging using an inter-subject normalization reference within the

Inventors                                Patent Application
AUSTIN ROBERT [US],LIM SHUANG FANG       Sem cathodoluminescent imaging using up-converting nanophosphors
AUSTIN ROBERT [US],LIM SHUANG FANG       Sem cathodoluminescent imaging using up-converting nanophosphors

Inventors                                 Patent Application
DOGRA VIKRAM [US],NG WAN [SG]             Robotic localizing aid for high intensity focused ultrasound delivery

Inventors                                 Patent Application
SAADAT VAHID [US],EWERS RICHARD C         Methods and apparatus for transmitting force to an end effector over
                                          an elongate member
SAADAT VAHID [US],PEH RUEY-FENG           Attenuation of environmental parameters on a gastric lumen

Inventors                          Patent Application
CHUA GIM GUAN [SG],SERRA LUIS [SG],NG     A method of rendering a graphics image
KOCKRO RALF A [SG]                        Dynamic display of three dimensional ultrasound ("ultrasonar")
KOCKRO RALF A [SG]                        Dynamic display of three dimensional ultrasound ("ultrasonar")
KOCKRO RALF ALFONS [SG]                   A guide system and a probe ther efor
KOCKRO RALF ALFONS [SG],LEE CHEE KEONG    Interaction with a three-dimensional computer model
SERRA LUIS [SG]                           System and method for displaying and comparing 3d models ("3d
SERRA LUIS [SG],KOCKRO RALF ALFONS        A display apparatus
SERRA LUIS [SG],LEE CHEE KEONG EUGENE     Methods and systems for interaction with three-dimensional computer

Inventors                                 Patent Application
LANE JOHN A [US],MCGRATH MICHELLE S       A portable vital signs measurement instrument and method of use
LANE JOHN A [US],MCGRATH MICHELLE S       A portable vital signs measurement instrument and method of use
A4 Profiles Key Research Institutes

A*STAR Bioinformatics Institute ....................................................................................... 39
A*STAR Institute for Infocomm Research ......................................................................... 42
A*STAR Institute of Bioengineering and Nanotechnology................................................ 45
A*STAR Institute of High Performance Computing (IHPC)................................................ 47
A*STAR Institute of Microelectronics (IME) ...................................................................... 49
A*STAR Singapore Bioimaging Consortium....................................................................... 52
A*STAR Singapore Immunology Network (Sign) ............................................................... 54
A*STAR Singapore Institute of Manufacturing Technology .............................................. 56
Becton Dickinson ............................................................................................................... 58
Biosensors International.................................................................................................... 60
Bracco Advanced Medical Technologies ........................................................................... 62
Fluidigm ............................................................................................................................. 64
HealthSTATS International ................................................................................................ 66
Hill-Rom ............................................................................................................................. 67
Nanyang Polytechnic ......................................................................................................... 69
Nanyang Technological University .................................................................................... 71
National Heart Center ....................................................................................................... 75
National University of Singapore....................................................................................... 77
Welch Allyn ........................................................................................................................ 79
A*STAR Bioinformatics Institute

1. General information
Website             http://www.bii.a-star.edu.sg/aboutBII.php
Description         The Bioinformatics Institute (BII) was set up by the Agency for
                    Science and Technology Research (A*STAR) in July 2001; it was re-
                    launched with a strong scientific program in the autumn months
                    of 2007. Located in the Biopolis, BII is conceived as the
                    computational biology research and postgraduate training
                    institute as well as a national resource centre in bioinformatics
                    within the Biomedical Research Council (BMRC) of A*STAR.
                    The BII focuses on theoretical approaches aimed at understanding
                    biomolecular mechanisms that underlie biological phenomena,
                    the development of computational methods to support this
                    discovery process, and experimental verification of predicted
                    molecular and cellular functions of genes and proteins with
                    biochemical methods.
                    Together with the BMRC, A*STAR research institutes and
                    multinational R&D organizations in the Biopolis, the BII is situated
                    in a conducive environment for exchange of scientific knowledge
                    and friendly interaction that will prompt greater collaborations,
                    and position the Biopolis as a notable biomedical R&D hub in Asia
                    and in the world.

3. Key Research

The Imaging Informatics Division is dedicated to the field of quantitative microscopy and
aims to automate the interpretation of images by applying methods in computer vision,
machine learning and statistics. The division consists of three groups that focus on "Live-Cell
Imaging and Automation of Image Analysis", "Computer Vision and Pattern Discovery" and
"Complex Cellular Phenotype Analysis".

Live Cell Imaging and Automation of Image Analysis
The group is interested in studying animal development using 3D time-lapse microscopy and
computer vision. Their principal goals are to develop protocols for live-cell imaging and
software tools for the automated analysis high content microscopy data. The group's
computational pipeline comprises preprocessing, segmentation, feature extraction and
classification (More Details). Their system is currently directed at the phenotypic
characterization of two biological processes in the model system Drosophila melanogaster;
(1) Cell cycle progression of embryonic cells and (2) apoptosis and remodeling of muscle cells
during metamorphosis. Contact: Dr. Martin WASSER, martinw@bii.a-star.edu.sg. Website:

      Live Cell Imaging by live video microscopy to classify phases of the cell cycle in
       embryos, and the destruction and remodeling of muscles in metamorphosis.
      Scene Interpretation of Live Cell Movies using Computer Vision: Design solutions that
       integrate preprocessing (deconvolution, noise reduction), segmentation and
       postprocessing such as morphological operators. Assign biological meaning to objects,
       after converting arrays of pixels into objects and extracting their feature values.

Computer Vision and Pattern Discovery
The group of Computer Vision and Pattern Discovery for Bioimages focuses on applying
advanced computer vision, machine learning and mathematical models to elucidate the
complex behavior of biological systems. The group analyses images from wide-field and
confocal microscopes, including image data sets from high-throughput screens. The trend
towards quantitative biology has spawned new areas of research, especially in the area of
digital imaging where thousands of images are acquired automatically through robotic
systems of chemical and cell assays handling. These images are then analyzed and used to
create new biological hypotheses that are further validated using other experimental means.
The group's contributions to high throughput, high content imaging are to provide accurate
and fast computational methods for the data mining of large image data sets. Contact: Dr.
LEE Hwee Kuan, Principal Investigator, leehk@bii.a-star.edu.sg. Web: http://www.bii.a-

      Cellular Phenotype Recognition
      Texture Segmentation Using the Subspace Mumford-Shah Model
      Entropy Regularization Feature Relevance for Texture and its Applications in
       Bioimage Processing
      Field Theoretical Method for Image Restoration
      Automatic and Quantitative Measurement of Neural Cell Outgrowths
      Biomedical Image Segmentation of Semi-transparent Objects Using a Variant of the
       Mumford-Shah Model
      A Multi-resolution Stochastic Level Set Method for the Segmentation of Bioimages
      Automated Nucleus and Cells Detection using a Region Based Ellipse Detector
      Automated Protein Distribution Detection in Images from High-throughput Image-
       based siRNA Library Screens

Complex Cellular Phenotype Analysis Discovery
The group is interested in systems biology and bioimage informatics. Systems Biology efforts
focus on investigating how complex biological systems respond to external perturbations.
They are especially interested in studying the effects of small molecules and hormones on
differentiating cells. Bioimage Informatics efforts focus on designing new computational
algorithms to extract biological information from microscopy images. Theyare also
developing efficient image processing tools for high-throughput phenotypic profiling assays.
Contact: Dr. LOO Lit Hsin, Principal Investigator, loolh@bii.a-star.edu.sg. Website:
4. Sources

A*STAR Institute for Infocomm Research

1. Contact Information
Contact name             Dr. Guan Cuntai
Position                 Programme Manager Intelligent Systems for Personalized and
                         Connected Healthcare (INSPECH)
Address                  1 Fusionopolis Way #21-01 Connexis, Singapore 138632
Tel./Fax.                (65) 6408 2663/ (65) 6776 1378
e-mail                   ctguan@i2r.a-star.edu.sg

2. General information
Research Staff      539 (as of 31 july 2010)
Website             http://www.i2r.a-star.edu.sg/index.html
Description         The Institute for Infocomm Research (I²R pronounced as i-
                    squared-r) is a member of the Agency for Science, Technology and
                    Research (A*STAR) family. Established in 2002, its mission is to be
                    the globally preferred source of innovations in `Interactive
                    Secured Information, Content and Services Anytime Anywhere’
                    through research by passionate people dedicated to Singapore’s
                    economic success. I²R performs R&D in information,
                    communications and media (ICM) technologies to develop holistic
                    solutions across the ICM value chain. Research capabilities are in
                    information technology, wireless and optical communication
                    networks, interactive and digital media, signal processing and
                    computing. They seek to be the infocomm and media value
                    creator that keeps Singapore ahead.
                    More than 70 researchers are involved in the Intelligent Systems
                    for Personalized and Connected Healthcare (INSPECH)
                    Programme, the institute’s medical technology programme.

3. Key Research

The INSPECH programme aims at developing and validating personalized and connected
“intelligent systems” for healthcare, which incorporate medical knowledge and innovative
technologies through clinical evaluations. The “personalized” systems will provide more
accurate diagnosis, or more efficacious treatment by taking the individual person’s medical,
physical, and cognitive conditions into consideration, therefore overcoming one-size-fits-all
problems in existing medical solutions. “Connectivity” is to ensure patients and medical
institutions are closely connected through the intelligent systems. Contact: Dr. Guan Cuntai,
Principal Scientist, Programme Manager Intelligent Systems for Personalized and Connected
Healthcare (INSPECH), ctguan@i2r.a-star.edu.sg Website: http://dicom.i2r.a-

      Mobile & Personal Healthcare
      Elderly & Home Care
      Intelligent Medical Imaging (iMed)
      Neural Computer Interface
Mobile & Personal Healthcare
MobiCare Web Portal is an extension of the MobiCare Project. It is based on ECG Signal
Processing. Contact: Chen Xiang, xchen@i2r.a-star.edu.sg

       Research to effectively classify Atrial Fibrillation (AF) from ECG signals
       Development of Personal Daily Ambulatory ElectroCardioGram monitoring systems
        (PDAECG) that can capture and analyze long-term ECG signals (>24 hours) in real-
Elderly & Home Care
The group run by Dr. Biswas Jit focuses on devices for home monitoring and Ambient
Intelligence for Home Care & Elderly Care. There is a collaboration with the Salvation Army
Peacehaven in Changi, a nursing home used as a testbed for new technologies. Contact: Dr.
Jit Biswas, biswas@i2r.a-star.edu.sg

     Monitoring of vital signs, events of daily life
     Cognitive support for people with mild dementia.
Intelligent medical imaging
iMED (Intelligent Medical Imaging) group is the medical image processing group in I2R
(Institute for Infocomm Research), with members from the Departments of Computer Vision
and Image Understanding, Data Mining, CGI (Computer Graphics & Interface) and the
INSPECH (Intelligent Systems for Personalized and Connected Healthcare) programme. The
iMED team focuses on developing a variety of medical image-based computer aided
diagnosis systems to assist healthcare providers in diagnosing illnesses. Contact: Dr. Liu Jiang,
Jimmy jliu@i2r.a-star.edu.sg Web: http://imed.i2r.a-star.edu.sg/

       SiRIAN: Singapore Retinal Image Archival and Analysis Network for Disease Prediction
       SSMS: Segmentation, Structure Modeling and Simulation (Aorta/Liver)
       MITE: Medical Image/video analysis for Therapeutic ingestible MicrocapsulE
       AGLAIA: Automatic GLaucoma Diagnosis and Its Genetic Association Study through
        Medical Image InformAtics
     IRAS: Image guided Robot Assisted Surgical training
Neural computer interface
The Brain-Computer Interface (BCI) Laboratory at Institute for Infocomm Research (I²R) is
dedicated to the research and development of neuro-technologies towards various
applications aiming at improving, restoring, monitoring, and training neural and cognitive
impairments or capabilities. Contact: Dr. Zhang Haihong, hhzhang@i2r.a-star.edu.sg, Web:

      ArtsBCI: Advanced rehabilitation therapy for stroke based on Brain-Computer Interface
      iSyNCC: Intelligent System for Neuro Critical Care, The project will develop a Neurologic
       Intensive Care Unit(NICU) informatics system which is able to handle enormous amount of
       data in real-time to provide clinicians with an accurate support platform so as to make
       intervention decisions.
      SEIZEµ: Automated video-EEG analytic system in seizure detection in the Epilepsy Monitoring
      Asynchronous and Adaptive P300 Brain-Computer Interface: A P300-based Brain-Computer
       Interface (BCI) is built upon event-related potentials (ERP). Its advantages lie in the ease of
       use and reliable performance.
      Brain-Computer Interface based Robotic Rehabilitation for Stroke: This project is a
       collaborative effort with Tan Tock Seng Hospital (TTSH) and the National Neuroscience
       Institute (NNI), in the area of stroke rehabilitation. It aims to develop the first neuro-
       rehabilitation system that combines non-invasive brain–computer interface (BCI) and robotic
       rehabilitation for patients suffering upper limb paralysis.
      Brain Computer Interface based Treatment for Attention Deficit and Hyperactivity Disorders
       (ADHD): developed a series of progressive training games using non-invasive
       electroencephalogram (EEG) based on Brain-Computer Interface (BCI). The BCI can quantify
       one’s attention level as measured by EEG waves, thereby allowing users to employ their
       attention to play these games directly. As the system makes use of a subject’s direct
       attention to control a game, it works on a feed-forward mechanism.
      Brain Controlled Wheelchair: built a brain-controlled wheelchair (BCW) that can navigate
       inside a familiar environment. The control strategy relies on our P300-based BCI so that the
       user can intervene at any time. After the user selects a destination on a menu, the
       wheelchair then moves to the corresponding target on a predefined path. This strategy
       requires minimal effort from the user.
      Brain-computer Interface based on Near Infrared Spectroscopy (NIRS): developed a Brain-
       computer Interface based on multichannel Near Infrared Spectroscopy (NIRS).

Volume Interactions is a spin-off of I²R. It focuses on interactive virtual reality systems for
radiology and surgery planning. The company has been acquired in 2002 by the Bracco

5. Collaboration interest, future perspectives.

There is a good match and collaboration interest with the Dutch medical imaging Cores (and
mainly image processing with Dr. Jimmy Liu), the extramural care Cores (Dr. Jit Biswas) and
the neurocontrol Core (Dr. Jit Biswas, Dr. Guan Cuntai).

6. Sources
A*STAR Institute of Bioengineering and Nanotechnology

1. Contact Information
Contact name             Dr. Benjamin Tai
Position                 Business Development
Address                  31 Biopolis Way #04-01 The Nanos, Singapore 138669
Tel./Fax.                (65) 6824 7000/ (65) 6478 9080
e-mail                   btai@ibn.a-star.edu.sg

2. General information
Website             http://www.ibn.a-star.edu.sg/index.php
Description         The Institute of Bioengineering and Nanotechnology (IBN) is an
                    institute under the BMRC. Since 2003, IBN has carved out a unique
                    niche at the interface of bioengineering and nanotechnology with
                    its impactful research. Led by Executive Director, Professor Jackie
                    Ying, the IBN conducts interdisciplinary research that brings
                    together science, engineering and medicine.
                    Committed to the pursuit of excellence in biomedical sciences and
                    guided by its mission of “Innovations for Tomorrow” of
                    Singapore's life science industry, IBN aims to provide international
                    leadership in bioengineering and nanotechnology, conduct
                    innovative research and create intellectual properties, play an
                    active role in technology transfer, and foster an exciting
                    multidisciplinary research environment for the training of students
                    and young researchers
                    Research area most relevant for medical device R&D is the
                    Biosensors and Biodevices research area. This research involves
                    the use of nanotechnology and microfabricated platforms for
                    high-throughput biomarkers and drug screening, automated
                    biologics synthesis, and rapid disease diagnosis.

3. Key Research

Biosensors and Biodevices
Biosensors and Biodevices, which involve nanotechnology and microfabricated platforms for
high-throughput biomarkers and drug screening, automated biologics synthesis, and rapid
disease diagnosis.
     A Fully Integrated Biochip for Early Cancer Diagnosis: This research aims to study and
       develop a fully integrated, automated, high sensitivity, low-cost molecular diagnostic
       that can be used in clinics and for point-of-care applications. We have designed a
       microfluidic system that can rapidly dissociate tumor tissue, isolate and analyze
       target cells, extract and purify mRNA, amplify genes, and detect the amplified genes.
       This biochip device provides for the possibility of early cancer diagnosis using solid
       tumor tissue samples. Contact: Zhiqiang Gao, goupleader, zqgao@ibn.a-star.edu.sg
      Microneedle Array for Transdermal Drug Delivery: Biotechnology has produced
       extremely sophisticated and potent drugs, but many of these drug compounds
       cannot be effectively assimilated by the body through oral medication or injections.
       Transdermal delivery of drugs is an attractive option, but is limited by the extremely
       low permeability of the skin. The primary barrier is located in the upper 10-15 µm of
       the skin, where the nerves are located. IBN researchers are developing microneedles
       of ~ 100 µm long, which would allow for skin penetration for drug delivery.
       Compared to the conventional hypodermic needles, these ultrafine needles would
       cause minimal pain to the patients. They are machined as a microsystem with a low
       flow resistance and a high strength, while providing for a large area of drug exposure
       to the tissue, lowering the risk for clogging. Besides transdermal delivery of vaccines,
       the microneedles can be used to sample biological fluids for diagnosis. Contact:
       Francis E. H. Tay, group leader ftay@ibn.a-star.edu.sg

4. Sources

A*STAR Institute of High Performance Computing (IHPC)

1. General information
Website             http://www.ihpc.a-star.edu.sg/index.php
Description         Established in April 1998, IHPC is a Research Institute under the
                    Agency for Science, Technology and Research (A*STAR), IHPC
                    promotes and spearheads scientific advances and technological
                    innovations through computational modelling, simulation and
                    visualisation methodologies and tools. Aim of the IHPC is to
                    provide leadership in high performance computing as a strategic
                    resource for scientific inquiry and industry development.
                    IHPC is committed to advancing science and engineering. The
                    Institute seeks to power discoveries through advanced
                    methodologies, techniques and new tools in modelling, simulation
                    and visualisation. Research foci are in the realm of large and
                    complex-coupled systems, mechanics and fluid dynamics, large
                    scale systems, computational electronics and electromagnetics,
                    computational material and chemistry, scientific computing and
                    software development, digital modelling, adaptive and
                    collaborative computing, data mining and analyses, and
                    knowledge based tool designs.

2. Key Research

The Advanced Computing (AC) Programme focuses on new paradigms in the future of
computing that will help to drive scientific and technological research. Researchers in the
Programme investigate techniques that draw out the efficiency, insight and quality in
computing technology in their respective domains.
At the processor level, the Programme is concerned about efficient algorithms that can
achieve faster research turnaround through high performance computing (HPC), and
generate insight through high-fidelity digital models, visualisation or data mining. At the
system level, the Programme focuses on system software that can best exploit system
infrastructure such as HPC clusters/servers. Another area of interest is in integrated software
platform that brings multi-disciplinary technologies together to power multi-disciplinary
science. Scaling out of an organisation into the distributed ecosystem, the Programme
investigates technologies that can enable effective collaboration of people and resources in
tackling large-scale complex problems. Website: http://www.ihpc.a-
      Patient-Specific Computational Cardiology
      Functional Assessment of Left Ventricle
      Haemodynamic Study
      Developing a quantitative computational approach for comprehensive assessment of
       left ventricular remodeling after myocardial infarction.
3. Sources
A*STAR Institute of Microelectronics (IME)

1. Contact Information
Contact name             Dr. Soo Choi Pheng, Ph.D
Position                 Research Manager
Address                  11 Science Park Road, Singapore Science Park II, Singapore
Tel./Fax.                (65) 6770 5301/ (65) 6778 0136
e-mail                   soocp@ime.a-star.edu.sg

2. General information
Research Staff      250
Website             http://www.i2r.a-star.edu.sg/index.html
Description         The Institute of Microelectronics (IME) is a member of the Agency
                    for Science, Technology and Research (A*STAR). Established in
                    1991 and ISO-9001 certified, IME's mission is to add value to
                    Singapore's semiconductor industry by developing strategic
                    competencies, innovative technologies and intellectual property;
                    enabling enterprises to be technologically competitive; and
                    cultivating a technology talent pool to inject new knowledge to
                    the industry.
                    R&D at IME covers the semiconductor technology chain, namely,
                    integrated circuit design, wafer fabrication process technology,
                    packaging and assembly, and reliability testing and analysis. These
                    R&D are classified under three laboratories, namely: Integrated
                    Circuits and Systems (ICS), Microsystems, Modules and
                    Components (MMC) and Semiconductor Process Technologies
                    IME has also established three application-driven programmes to
                    focus its R&D efforts in new technologies and open up new
                    opportunities for the semiconductor industry: Bioelectronics (BE)
                    Programme, Nano Electronics and Photonics Programme, and the
                    Sensor & Actuator Microsystems (SAM) Programme. Medical
                    devices are developed within the bioelectrronics programme.
3. Key Research

The BE programme is posed to make a rapid intellectual and economic impact in the
bioelectronics area, by leveraging on its expertise across the entire value chain of
microelectronics and know-how accumulated over the years through collaborative projects
with local universities, research institutes, and industry. The R&D efforts of the programme
have evolved in two main thrusts: Point-of-Care (POC) diagnostics and Miniaturized Medical
Device (MMD).

Point-of-Care (POC) Diagnostics
Devices and systems that could detect clinically-significant disease markers non-invasively
(from a fingerprick for example) and rapidly, are foreseen to critically impact healthcare. The
specific needs for such systems and ultimately for an integrated programme has arisen
through discussions with various end-users of IME's technologies, and more particularly
clinicians. All these undertakings are constantly reshaped via direct interaction with experts
from prominent centers, potential end users, such as Tan Teck Sang Hospital for infectious
diseases, National Heart Center and Singapore Gastric Cancer Consortium. Specifi cally,
doctors ask for POC systems to diagnose infectious diseases (dengue), cardiovascular
diseases (acute myocardial infarction or heart attack), and cancer (gastric).
Since the inception of the programme, many of the projects have spawned individual
micromodules for nucleic acid analysis, particularly for sample preparation and amplification,
thereby preparing the groundwork for an integrated point-of-care diagnostic unit. On the
other end of the process, the programme has developed biosensor modules for sample
detection that shows high sensitivity and repeatability and can be easily integrated with the
upstream modules. Among the modalities investigated for the detection of macromolecules
such as nucleic acids and proteins, research has focused mainly on a label-free electrical
detection method utilizing the intrinsic electrical charge of molecules as a native label. From
these modules, research activities are now focused on integrating all the necessary functions
in simple complete systems that will be easily implemented near the patient.
Cell-Based Diagnosis
     Bedside Detection of Rare Circulating Cells for Rapid Cardiovascular Treatment
     Detection of Circulating Tumour Cells for Cancer Therapy Monitoring
     Integrated System for Patch-Clamp on Chip
Molecular Based Diagnosis
     Detection of Infectious Diseases
     Detection of Cardiac Biomarkers for Cardiovascular Diagnostics
     Detection of Low Affinity Molecular Interactions For Drug Discovery

Miniaturized Medical Devices
Miniaturized medical devices are a major opportunity for advancing Medtech into new
avenues by enhancing medical technology and making it affordable to all. IME researchers is
designing, fabricating, packaging (biocompatible) and testing highly sensitive and
miniaturized Microelectromechanical systems (MEMS) that can measure physiological
parameters for medical applications. All these are integrated with an Application Specific
Integrated Circuits (ASIC) and wireless interface circuits with only ultra-low power
The following applications and associated technologies are currently under pursuit in
collaboration with the academia and collaboration with local medical partners such as
National University Hospital (NUH), Alexandra Hospital, Singapore General Hospital (SGH)
and National Neuro Institute (NNI).

      Wireless Bio Imaging System
      Endoscopic Probe for Optical Coherence Tomography (OCT) System
      Wireless Neuro Motor Prosthesis
      Needle Size Ultrasound Imager

4. Sources
A*STAR Singapore Bioimaging Consortium

1. Contact Information
Contact name             Dr. Kishore Bahkoo
Position                 head Translational Molecular Imaging Group
Address                  11 Biopolis Way #02-02 Helios, Singapore 138667
Tel./Fax.                (65) 6478 8732/ (65) 6478 9957
e-mail                   Kishore_bhakoo@sbic.a-star.edu.sg

2. General information
Website             http://www.sbic.a-star.edu.sg/index.php
Description         The Singapore Bioimaging Consortium (SBIC) aims to build a
                    coordinated national programme for imaging research, bringing
                    together substantial strengths in the physical sciences and
                    engineering and those in the biomedical sciences. SBIC seeks to
                    identify and consolidate the various bioimaging capabilities across
                    local research institutes, universities and hospitals in order to
                    speed the development of biomedical research discoveries.
                    SBIC's intramural programme comprises eight research units,
                    namely the Magnetic Resonance Imaging Group (MRIG),
                    Translational Molecular Imaging Group (TMIG), Magnetic
                    Resonance Spectroscopy/Molecular Imaging (MRS/MI) Group, PET
                    and SPECT Development Group, Bio-optical Imaging Group (BOIG),
                    Lab of Metabolic Medicine (LMM), Lab of Bioimaging Probe
                    Development (LBPD) and Biomedical Imaging Lab (BIL)

3. Key Research

The Singapore BioImaging Consortium (SBIC) plans to create an integrated platform for
multidisciplinary research involving biologists, chemists, physicists, electrical engineers,
computer scientists and clinician scientists to work together in a coordinated manner. SBIC
will also provide a focal point of interaction with pharmaceutical and biotechnology
industries to explore joint research collaborations or business ventures.

Four technology platforms have been identified used to support research in areas such as
cancer, metabolic medicine and regenerative medicine:
i) Optical imaging
ii) Image processing and management
iii) Small animal imaging with Magnetic Resonance
iv) Development of Chemical/ Biological probes
Translational Molecular Imaging Group
The Group's work focuses on one of the key questions when using stem cells to repair tissues:
do the cells get to the target and remain at the lesion site? Cell therapists need to follow
stem cells for weeks, months and even years after they are transplanted. The development
of multimodal imaging (MRI, PET, SPECT/CT and Optical) methodologies for monitoring
implanted stem cells in vivo will greatly facilitate the clinical realisation and optimisation of
stem cell based therapies. Moreover, these multi-modal methodologies will also be used to
interrogate a number of other pathologies, such as the Immune system and Cancer. Contact:
Kishore Bahkoo, PhD., head Translational Molecular Imaging Group, kishore_bhakoo@sbic.a-
star.edu.sg Web: http://www.sbic.a-star.edu.sg/research/tmig/index.php

    To engineer polymer-enveloped super-paramagnetic nanoparticles specifically for cell
     labeling for MRI studies.
    Develop contrast agents for other imaging modalities such as PET, SPECT and Optical.
    To develop generic methodologies for the tracking of cells in vivo using MRI and PET.

Biomedical Imaging Lab
The Biomedical Imaging Lab has numerous years of experience in medical imaging. This
group's R&D activities have concentrated on neuroimaging with expertise in anatomic and
functional atlases and atlas-based applications, computer-assisted intervention, human body
models, medical devices, and biomedical imaging tools. This research involves segmentation,
geometric and physical modeling, visualization, registration, tactile feedback, shape analysis,
and virtual reality. The group has a solid track record in technology transfer. We have
developed nine brain atlas products that are being used world-wide in neurosurgery, brain
mapping, neuroradiology, and neuroeducation. Our brain atlas is established as the gold
standard in functional neurosurgery, licensed to Medtronic, BrainLab, Elekta, Surgical
Navigation Network, Integrated Surgical Systems, and Mayo (integrated with Analyze).
Cerefy is a spin-off from the group. Contact: Nowinski Wieslaw, SBIC@sbic.a-star.edu.sg
Website lab: http://www.sbic.a-star.edu.sg/research/bil/index.php. Website spin-off:

    Brain atlas
    Planning and performing stereotactic and functional neurosurgery for treatment of
     Parkinson's Disease and other related surgeries.
    Identifying brain structures in diagnostic neuroradiology.
    Medical training and education.
    Medical imaging research.

4. Sources

Website: http://www.sbic.a-star.edu.sg/research/bil/index.php
A*STAR Singapore Immunology Network (Sign)

1. Contact Information
Contact name              Alexandre Gouaillard
Position                  Principal Investigator
Tel./Fax.                 /
e-mail                    alexandre_gouaillard@immunol.a-star.edu.sg

2. General information
Website             http://www.sign.a-star.edu.sg/
Description         SIgN was initiated by BMRC in 2005 to build up research mass and
                    coordinate basic, translational and clinical research needed to
                    establish immunology as a core capability in Singapore.
                    SIgN focuses on studying immune responses in disease-specific
                    contexts to build up a strong platform in basic human immunology
                    research for better translation into clinical applications. Building
                    on the strengths of existing research groups at A*STAR, it has
                    expanded on productive links within A*STAR and across
                    Singapore, as well with leading institutions in the world, and has
                    established a name for Singapore in the critical discipline of
                    immunology. SIgN’s chairman is Professor Philippe Kourilsky and
                    its Scientific Director is Professor Paola Castagnoli.

3. Key Research

The immune system represents a complex adaptive system, meaning that you can not
understand or predict its behavior as a whole even when you understand the individual
behaviors of its component parts. This is where complex systems modeling comes in. At SIgN
we take advantage of a complex systems based modeling and simulation software platform
called CoSMo. This platform enables us to integrate every piece of information that
scientists collect during their research, thereby significantly increasing the power of the data
for biological problem solving.
Using the csmXML language, we can build up conceptual models of biological networks.
CoSMo then allows us to automatically infer the corresponding computational models that
can be used to simulate the evolution of the network across time and deduce its dynamics.
All leading to a better understanding of the complexity of the immune system. Currently we
are collaborating with other SIgN scientists on a wide range of projects: the role of the tumor
immune microenvironment in cancer progression, the existence and emergence of cytokine
fields, as well as the influence of danger signals on immune cell fate.
Since 2003, Dr Gouaillard has been actively involved in the development of NIH’s NLM’s
Insight Toolkit. As a member of the editorial committee he oversees parts of the Toolkit
especially dealing with Discrete Meshes. Between 2005 and 2007, he acted as a R&D
Engineer at the SUN Microsystems Engineering and Research Institute in Beijing, PRC, where
he developed Hardware acceleration support for OpenGL in OpenSolaris.
Between 2007 and 2009, he worked first at Caltech then at Harvard Medical School, Systems
Biology Department, as a research associate involved in a multi-institution Center For
Excellence in Genomic Science (CEGS). He focused on Gene Expression Data Extraction from
Embarrassingly large Fluorescent Confocal Microscopy Datasets (TeraBytes).
He was also the chief designer and main developer of GoFIgure 2, a software which assists
the integration and diffusion of this research to the broader microscopy, biology and image
processing communities. In addition he has co-founded two biotech start up companies in
Lyon, France, and Cambridge, MA, USA. Contact: Dr. Alexandre Gouaillard,
alexandre_gouaillard@immunol.a-star.edu.sg, Website: http://www.sign.a-
A*STAR Singapore Institute of Manufacturing Technology

1. General information
Website             http://www.simtech.a-star.edu.sg/simcorp/index.do
Description         The Singapore Institute of Manufacturing Technology (SIMTech)
                    develops high value manufacturing technology and human capital
                    to enhance the competitiveness of Singapore's manufacturing
                    industry. It is a research institute of the Agency for Science,
                    Technology and Research (A*STAR).
                    SIMTech has completed more than 900 projects with more than
                    500 companies, big and small, in the electronics, semiconductor,
                    precision engineering, medical technology, aerospace,
                    automotive, marine, logistics and other sectors.
                    Roles are:
                         To create intellectual capital through the generation,
                            application and commercialisation of advanced
                            manufacturing science and technology
                         To nurture Research Scientists and Engineers by providing
                            opportunities to do use-inspired research for industry
                         To contribute to Singapore's industrial capital by
                            collaborating in projects and sharing research expertise
                            and infrastructure with industry

3. Key Research

Microfluidics Manufacturing Programme (MMP)
The programme develops the manufacturing platform for microfluidic devices to support the
advanced process and product innovations for microfluidics applications in biomedical
diagnosis and research, chemical processing, water treatment, energy and other industries.
Microfluidic devices have shown great potentials in chemical analysis, biomedical detection
and diagnostic applications. However, many biochips are fabricated using silicon wafers or
glass slides. Due to the batch process nature of the etching process, chips manufactured this
way are expensive for disposable applications. Polymer materials, on the other hand, have
better properties for many fluidic samples analysis and can be mass fabricated at low cost
for many disposable applications. The main focus of the programme is to develop the
capabilities in design, fabrication and characterisation techniques for polymer-based
microfluidic devices.

Product Innovation and Development (PID)
The PID programme draws expertise from SIMTech’s technologies to generate,
conceptualise and implement ideas into different products and solutions. Hence ideas have
many opportunities to be developed into multiple products, and marketed in more product
PID is currently developing its product design and development methodology to ensure
quality delivery of the end-products as well as leveraging on the broad and in-depth research
capabilities of the Agency for Science, Technology and Research (A*STAR) in biomedical
materials, nanotechnology, microfluidic devices to enhance medical device product design
PID is currently working with market leaders to create user-friendly medical devices. In the
medical arena, PID has embarked and completed successfully collaborations for the local
healthcare and international medical industries. Some of these include
     feasibility study and patent analysis of disposable body fluid test kit;
     product design for disposable scalpel;
     safety needle and children’s toothbrush;
     system analysis and solving manufacturing problems of pulsewave pump device.
4. Sources
Becton Dickinson

1. Contact Information
Contact name
Address                   30 Tuas Avenue 2, Singapore, 639461
Tel./Fax.                 65.6861.0633/ 65.6860.1593

2. General information
Revenue             US$ 7,160,874 (FY ending Sep. 30, 2009)
Employees           29,116
Website             http://www.bd.com/
Description         Becton, Dickinson and Company (BD), is an American medical
                    technology company that manufactures and sells medical devices,
                    instrument systems and reagents. Founded in 1897 and
                    headquartered in Franklin Lakes, New Jersey, BD does business in
                    nearly 50 countries and has 29,116 employees worldwide. In fiscal
                    year ending Sep. 30 2009, 60% of BD sales were generated from
                    non-U.S. markets.
                    The company's customers include healthcare institutions, life
                    science researchers, clinical laboratories, industry and the general
                    public. BD was one of the first companies to sell U.S.-made glass
                    syringes. It was also a pioneer in the production of hypodermic
                    needles. Today, BD is divided into three segments: BD Medical, BD
                    Diagnostics and BD Biosciences. In 2009, BD was ranked 347 in the
                    Fortune 500 list.
                    R&D in Singapore is part of BD Medical and includes R&D on
                    needles, syringes and intravenous catheters. There is also a branch
                    aimed at ophthalmic systems.

3. Key Research

BD Medical
The BD Medical segment consists of four divisions: Medical Surgical Systems, Pharmaceutical
Systems, Diabetes Care, and Ophthalmic Systems. The products of this segment include:
needles and syringes, intravenous catheters, safety-engineered and auto-disable devices,
prefillable drug delivery systems, prefilled IV flush syringes, insulin syringes and pen needles,
regional anesthesia needles and trays, surgical blades and scalpels, ophthalmic surgical
instruments, and critical care products. Patents have been applied for by Alvin Tan Chee
     Flashback blood collection needle
     Catheter having a low drag septum
     Roller wheel assisted guidewire advancer
4. Sources

Patent analysis
Biosensors International

1. Contact Information
Contact name              Biosensors Interventional Technologies Pte Ltd
Address                   Blk 10, Kaki Bukit Avenue 1, #06-01/04, Kampong Ubi
                          Industrial Estate, Singapore 417942
Tel./Fax.                 +65 6213 5777/ +65 6213 5737

2. General information
Revenue             USD $37.8 Million (2006)
Website             http://www.biosensors.com/
Description         Biosensors International Group is a medical device company that
                    specializes in developing, manufacturing and licensing
                    technologies for use in interventional cardiology procedures and
                    critical care. The company was listed in the Mainboard of the
                    Singapore Exchange (SGX) in May 2005. The global headquarters
                    of the company are located in Singapore, where the main
                    manufacturing facilities and R&D centers are hosted. The
                    European headquarters are in Morges, Switzerland; this Swiss
                    office is also the Legal Manufacturer of BioMatrix, the current
                    leading product of the company.
                    Biosensors has obtained CE Mark for this drug-eluting stent
                    product in January 2008. To enter the China market, Biosensors
                    has set up a joint-venture with Hong Kong listed Shandong Weigao
                    to market and distribute coronary stents in China.
                    As one of the few companies with proprietary drug-eluting stent
                    technology, Biosensors also has been obtaining revenue through
                    licensing its technologies to other medical device companies like
                    Terumo, and specialty-stent providers like Devax, Inc. and Xtent,

3. Key Research

Initially, R&D was focused on vascular catheters and blood pressure transducer systems for
open-heart surgery and critical care. Now, developing future generation drug -eluting stents
and other innovative products to address the challenges of cardiovascular disease is focused
on. Website: http://www.biosensors.com/intl/about-biosensors-pipeline-rd
      Drug eluting stents
      Recent patent applied for in Singapore: an apparatus and method for determining the length
       and size of stents to be
4. Sources

Patent analysis
Bracco Advanced Medical Technologies

1. General information
Website             http://www.volumeinteractions.com/
Description         BRACCO AMT, Inc., previously Volume Interactions Pte Ltd., is the
                    developer of Volumetric Interactive 3D, a virtual reality
                    technology to advance 3D imaging. It is a spin-off from the
                    Institute for Infocomm Research
                    BRACCO AMT, Inc. is a member of the Bracco Group, a world
                    leader in global solutions for the diagnostic imaging field. As such,
                    BRACCO AMT develops solutions that complement the Bracco
                    Group line of contrast agents and contrast delivery systems and
                    add value in a postprocessing environment to visualize and
                    manipulate scanner images.
                    The technology fuses multimodality patient images into 3D
                    volumetric objects that can be segmented and manipulated to
                    determine the most effective surgical approach. By presenting a
                    3D stereoscopic model of the patient’s anatomy for rehearsal of
                    surgery, the technology adds speed, ease, and precision to surgical
                    planning and education.
                    BRACCO AMT renders the images in a volumetric way and adds
                    real-time interaction, Volumetric Interactive 3D tries to give
                    neurosurgeons an easier way to explore surgical options.

2. Key Research

Bracco AMT develops interactive, 3D visualization technology for surgical planning. It has
two main products, the Dextroscope and the Dextrobeam. Dextroscope supports surgical
evaluation and decision-making at a level previously only imagined and gives you an
unprecedented understanding of complex anatomical relationships and pathology.
Dextrobeam uses a projector and takes the capabilities of Dextroscope to the large screen.
Contact: Website: http://www.volumeinteractions.com/ps.html
Recent patents applied for:
      Stereo display of tube-like structures and improved techniques therefor ("stereo display")
      System and methods for screening a luminal organ
      Dynamic crop box determination for optimized display of a tube-like structure in endoscopic
       view ( crop box")
      Dynamic crop box determination for optimized display of a tube-like structure in endoscopic
       view ("crop box")
      Stereo display of tube-like structures and improved techniques therefor ("stereo display")
      System and methods for screening a luminal organ "lumen viewer" - system and methods for
       screening a luminal organ
      Apparatus for medical and/or simulation procedures
      Apparatus for medical and/or simulation procedures

3. Sources

Patent analysis

1. General information
Website             http://www.fluidigm.com/
Description         Fluidigm develops systems based on integrated fluidic circuits
                    (IFCs). IFCs play a vital role in the advancement of today’s life
                    science and allied fields, including molecular diagnostics,
                    personalized medicine, and wildlife conservation. With IFCs,
                    scientists are able to conceive of and implement large, complex
                    studies that further our knowledge of biology.
                    The evolution of the life science may be compared to that of the
                    electronics industry, in which the integrated circuit replaced
                    transistors and wiring for routing electricity, sparking exponential
                    increases in speed and complexity of computing. Like electronic
                    circuits, IFCs are fabricated using a photo lithographic process, in
                    this case, to pattern molds for producing silicone wafers that have
                    microscopic channels, pumps, valves, and other components
                    needed for the manipulation of nano-volume scale fluids. These
                    components can be densely arrayed for parallel operations,
                    without loss of reliability (1).
                    Their chips are now mainly used in biomedical research labs. Next
                    step would be to develop devices that makes cheap diagnostics
                    possible (2).
                    Fluidigm is an American company but has important R&D facilities
                    in Singapore. Their Biomedical Product Development Center in
                    Singapore is a core part of Fluidigm’s worldwide R&D organization
                    and is responsible for the development of a Fluidigm Biomark II
                    series. Recently, Fluidigm has expanded its R&D facilities in
                    Singapore (3).

3. Key Research

Fluidigm accelerates its R&D and manufacturing activities in Singapore, through the launch
of a new Biomedical Product Development Center. This center, a core part of Fluidigm's
worldwide R&D organization, will be responsible for the full development of a Fluidigm
BioMark II series of instrumentation.
The center's initial research activities will support the development of instrumentation for
the BioMark II system. The Singapore research group will undertake 100% of the R&D on a
new biochip fluorescence reader and biochip loader, specially designed for high-throughput
genotyping and protein expression applications. Fluidigm Singapore will also manufacture
the BioMark II system.
Operations for the Biomedical Product Development Center will commence immediately,
with its current R&D team of 5. Additional staff will be recruited from Singapore's pool of
manufacturing and research expertise. The R&D center will also be supported by the local
precision engineering companies, academic, biomedical and pharmaceuticals research
institutions. (4)
4. Collaboration interest, future perspectives.
Fluidigm eventually will have to broaden its market by developing diagnostic applications for
its microfluidics chips. Researchers at Memorial Sloan-Kettering Cancer Center, in New York,
are studying whether Fluidigm’s technology can be used to analyze gene expression in
patients’ cancer cells, with the aim of using that information to choose the most appropriate
drug for an individual. A key component of entering the diagnostics market will be
developing a small desktop or handheld device to analyze its chips, which could be used in
doctor’s offices and in clinics (2).

4. Sources:

1. http://www.fluidigm.com/about/
2. http://www.technologyreview.com/companywatch/company/fuidigm/
3. http://www.genomeweb.com/arrays/fluidigm-expand-singapore-operations-meet-rise-rd-
4. http://www.analytica-world.com/news/e/61490/
HealthSTATS International

1. General information
Website             http://www.healthstats.com/en
Description         HealthSTATS International is a privately held Singapore-based
                    technology company with principal activities in research &
                    development, sales & marketing of innovative bio-monitoring
                    devices for hypertension and related illnesses.
                    Aim is to be one of the global leaders in the medical technology in
                    enhancing lives by providing the medical community with
                    evidence-based approach to Predicting & Diagnosing, Customised
                    Treatment, Monitoring and Informing of patients of their clinical
                    outcomes with evidence-based medicine for hypertension and
                    related illnesses. The effective management of hypertension will
                    lead to better standard of patient care.

2. Key Research

HealthSTATS technology branded as "EVBP™ – evidence-based blood pressure" is expected
to significantly revolutionize the way blood pressure is being monitored, treated and
managed worldwide. EVBP™ will be the platform on which HealthSTATS medical devices will
be developed and manufactured.
HealthSTATS patented 24-hr ABPM and Pulse Wave technologies are both novel. These
revolutionary technologies are expected to change the ways hypertension is being measured
and diagnosed. HealthSTATS BPro™ portable continuous blood pressure monitoring device
with its innovative technology of monitoring blood pressure has the potential to reduce the
risk of a sudden heart attack or stroke.

3. Sources


1. General information
Revenue             $1.507 billion USD (2008)
Employees           6,500 (2004)
Website             http://www.hill-rom.com/
Description         Hill-Rom, Inc., is a company that makes hospital beds, furniture,
                    other health care equipment, and medical technology systems.
                    Hill-Rom is a wholly owned subsidiary of Hill-Rom Holdings, Inc.,
                    and a former subsidiary of Hillenbrand Industries. In October
                    2008, Hill-Rom acquired Sweden-based Liko, a manufacturer of
                    mobile and stationary patient lift systems and associated
                    accessories for $183M.
                    The company has their primary offices and manufacturing facilities
                    in Acton, MA, Batesville, IN, Cary, NC, Charleston, SC, Montpellier,
                    France, Pluvigner, France, and as well as a multitude of offices and
                    service centers around the world.
                    Hill-Rom has established its Asia-Pacific Innovation Centre in
                    Singapore to focus on applied development in micro-electronics,
                    embedded software and electro-mechanical systems, all of which
                    are integral to the development of new Hill-Rom beds and therapy
                    surfaces. The centre will also be the home-base for new teams
                    looking at R&D projects for global applications of Hill-Rom
                    In 2010, Hill-Rom launched the Patient Support Development
                    Center in Singapore. This centre will collaborate with hospitals in
                    Asia to develop new products for the region. Hill-Rom also
                    launched a Respiratory Care Development Center that will identify
                    and develop innovative global respiratory care products in

2. Key Research

The Asia-Pacific Innovation Center officially opened in August 2008. Currently, 40 Hill-Rom
employees work at the location, comprising Hill-Rom's R&D teams, and sales and marketing
staff in the region. The Innovation Center in Singapore initially opened with 11,000 square
feet of space and has now been expanded by two new Research and Development (R&D)
centers of excellence.
The new areas of focus include a Respiratory Care Development Center that will identify and
develop innovative global respiratory care products expanding beyond Hill-Rom's high
frequency chest wall oscillation therapy known as The Vest® Airway Clearance System. Also
new is a Patient Support Development Center that will focus on developing a variety of
technology solutions for emerging markets.
The respiratory care R&D teams will focus on developing new technologies and products for
the global mechanical airway clearance market while other R&D teams continue to focus on
products for the medical-surgical environment, new bed technologies and connectivity

3. Sources

EDB: http://www.edb.gov.sg/edb/sg/en_uk/index/news/articles/hill-rom_expands_asia-
Nanyang Polytechnic

1. Contact Information
Contact name             Mr Leonard Loh
Position                 Manager Biomedical Engineering Group
Address                  Nanyang Polytechnic, 180, Ang Mo Kio Avenue 8, S569830
Tel.                     6550-0664
e-mail                   Thambyrajah_T@nyp.gov.sg

2. General information
Staff               1400
Website             http://www.nyp.edu.sg/
Description         Nanyang Polytechnic (NYP) is a Singaporean polytechnic located in
                    Ang Mo Kio next to Yio Chu Kang MRT Station, Singapore. The
                    institution houses 14 administration blocks, three blocks for
                    recreational and student development purposes and three blocks
                    for staff accommodation.
                    The campus is modelled on a town-centre concept to provide the
                    conveniences of a self-contained "Teaching and Learning City".
                    Facilities include a fully-computerised library, laboratories, a 300-
                    seater Theatre for the Arts and a 1,200-seater auditorium. The
                    staff apartment blocks are located within the campus.
                    The School of Engineering (SEG) at NYP has over the years
                    established a firm foundation of partnerships with foreign
                    governments and industrial leaders. With these partnerships, SEG
                    has set up various Specialist Centres to better cater to the needs
                    of students so that they will be exposed to new and emerging
                    To date, SEG has fifteen Specialist Centres that continue to
                    enhance the learning process of the students including a
                    biomedical engineering hub.

3. Key Research

Biomedical Engineering Hub
The Biomedical Engineering Hub provides infrastructure and synergy among all
complementary competencies and resources related to Biomedical Engineering for the
complete value chain in the development of medical devices from design, testing and
validation, to tooling stage. Product range include Medical Diagnostics, Disposables,
Implants and Therapeutic Systems.
Apart from using the multi-disciplinary engineering capabilities, the Biomedical Hub have
expertise in fields like Medical Device Design, Medical Imaging, Medical Validation and
Biomaterials to work on areas like medical devices & implants, biosensors & instrumentation
and computation bioengineering.
As the Biomedical Engineering Hub provides support and infrastructure/resources related to
Biomedical Engineering for the complete value chain in the development of medical devices
from initial stages of design to tooling and rapid prototyping stage we have been involved in
a number of projects which showcase our diverse competencies.
     Medical Imaging: Scanned medical images (CT, MRT & PET) from the hospitals can be
       combined and processed to form 3D volumetric images. 3D images allow doctors
       better understanding of the problem area. One such application is in cancer
       detection for accurate diagnosis and intervention.
     Hydrothermal Endometrial Ablation Device: The aim of this project is to design a
       hydrothermal endometrial ablation device for the treatment of Menorrhagia.

Centre for Technology Innovation & Commercialisation (CTIC)
The CTIC was established to serve as a platform to:
     Protect & manage intellectual property at NYP
     Perform market and technology assessment services
     Provide staff training and capability development in technology transfer
     License and work on collaboration or partnership agreements
     Coordinate innovation grants
     Facilitate technology transfer to industry
CTIC provides patenting, licensing, and other commercialisation support to our staff and
students to foster innovation and entrepreneurship. We also work closely with companies to
design and develop customised solutions suited to their needs. We have many technologies
available for licensing, namely in the domains of Biotechnology, Computers & IT, and
Engineering. Website: http://www.nyp.edu.sg/ctic

EDB’s MedTech Concept
The Biomedical Hub actively supports MedTech Concept activities. MedTech Concept is an
EDB initiative hosted by NYP, which provides activities and infrastructure, funding and
incubator support for new medical technology company startups. This support encourag es
the increase in applied research and development in medical technology devices and
applications in Singapore

4. Sources

Patent analysis
Nanyang Technological University

1. Contact Information
Contact name             Louis Phee
Position                 Ass. Prof. School of Mechanical & Aerospace Engineering
Address                  50 Nanyang Avenue, n3.1-B2c, Singapore 639798
Tel./Fax.                +65 6790 4959/ +65 6792 4062
e-mail                   msjphee@ntu.edu.sg

2. General information
Endowment           S$914 million
Faculty             1,100
Website             http://www.ntu.edu.sg/
Description         Nanyang Technological University (NTU) is a research university in
                    Singapore. The university's main campus, known as the Yunnan
                    Garden campus, is in the south-western part of the island. It
                    houses Singapore's largest on-campus residence infrastructure
                    including 16 halls of residence for undergraduates and a graduate
                    hall. In 2009, it has been ranked 73rd in THE-QS World University
                    Rankings (From 2010 two separate rankings will be produced by
                    the Times Higher Education World University Rankings and the QS
                    World University Rankings). It is a founding member of Global
                    Alliance of Technological Universities.
                    The Biomedical & Pharmaceutical Engineering (BPE) Cluster at
                    NTU serves to consolidate research in bioengineering and
                    pharmaceutical engineering technologies by integrating multi-
                    disciplinary expertise. It oversees and coordinates the research
                    carried out at its 5 major research centres and laboratories, 3 of
                    which are involved in medical technology research. These are the
                    Biomedical Engineering Research Centre (BMERC), Computer
                    Integrated Medical Intervention Laboratory (CIMIL) and the
                    Physiological Mechanics Laboratory (PML).

3. Key Research

BMERC was established in January 1998 as an inter-school joint effort within NTU to conduct
multi-disciplinary research activities. Researchers in the centre come from Schools of
Chemical & Biomedical Engineering, Computer Engineering, Electrical & Electronic
Engineering, Materials Science & Engineering as well as Mechanical & Aerospace Engineering.
The centre also has collaboration work with the School of Civil & Environmental Engineering,
National Institute of Education as well as School of Biological Sciences.
The vision of the centre is to act as a synergy between Medical Doctors, Biologists, Industry,
and Engineers, for direct practical application of research results and developments, leading
to new sophisticated methods and products. BMERC will focus on Biomedical Engineering
research in NTU, especially on niche and thrust areas. It will also serve to promote
collaborative R&D projects with local and overseas healthcare facilities, academic research
institutes and private industry, in addition to providing consultancy services and professional
training in Biomedical Engineering. http://www.ntu.edu.sg/bmerc/contents/

Many patents in the therapeutic acoustics field have been applied for by Dr. Sunita Chauhan.
Her current research interests include Medical/Surgical Robotics, Computer Assisted and
Integrated Surgery, Medical Ultrasound (Imaging, Therapeutic and Surgical ultrasound), Bio-
sensors, Image and Sensor data processing/fusion/interpretation. Contact: Dr. Sunita
Chauhan, Associate Professor Division of Mechatronics and Design, MCSunita@ntu.edu.sg,
      A bio-mechatronic approach for minimally-invasive surgery using focal ultrasound induced
      Bio-mechatronic, minimally invasive surgical suite for alblation of neurosurgical indications.

Dr. Louis Phee develops robotics systems for endoscopic surgery as well as capsule
endoscopy. Key is that his technology enables intuitive procedures that would be impossible
to perform without using robotics technology. Where the DaVinci can do straightforward
laparoscopic procedures, his surgical robot will enable NOTES (natural orifice transluminal
endoscopic surgery), a complicated surgical technique that enters the body through natural
orifices rather than making external incisions. This year his technology will be the first in
patient robotics NOTES procedure in a clinical trial. Another key research area is developing
a capsule endoscope with therapy capabilities, such taking biopsies and marking important
places in the body. Current efforts are aimed at developing a gastric balloon capsule with a
2-way communication platform that would provide a minimal invasive alternative for gastric
balloon procedures in obese people. Contact: Louis Phee, PhD, Deputy Director,
Mechatronics & Control Laboratory, msjphee@ntu.edu.sg. Website:
      W.S. Ng, L. Phee, F. Seow-Choen, “Robotic Endoscope and an Autonomous Pipe Robot for
       Performing Endoscopic Procedures”, U.S. Patent 6,162,171, December 2000.
      L. Phee, A. Arena, A. Menciassi, P. Dario, “Endoscopic Device for Locomotion through the
       Gastro-intestinal Tract”, U.S. Patent 6,939,291, September 2005.
      L.Phee, R.E.Oakley, H.S. Lim, “Intuitive Control Device for Motorized Furniture”, May 2003,
       (Patent Pending)
      L.Phee, D. Xiao, J. Yuen, C.H. Thng, P.H. Tan, W.K.O Lau, H. Ho, W.S. Ng, C.W.S. Cheng,
       “System and Method for Accurate Percutaneous Needle Placement in Soft Tissue Under
       Ultrasound Guidance”, April 2004, (U.S. Provisional Patent Application)
      L.Phee, K.Y. Ho, S.C. Low, S.W. Tang, S.C. Chung, “Surgical Robotic System for Flexible
       Endoscopy”, US Provisional Application no. : 60/785,985, 27 Mar 2006.

Dr. Ang Wei Tech’s group is focused at robotics for rehabilitation research and for
microsurgery. Topics include motivation for training functional tasks and using a Brain
Computer Interface to include intention into tasks. Important focus is on stroke
rehabilitation, Singapore has one of the highest stroke rates in the world. Microsurgery
research is aimed at identifying and reducing tremor caused by the surgeon’s hand and at
quantifying surgeon skill. Contact: Dr. Ang Wei Tech, Ass. Prof. School of Mechanical &
Aerospace Engineering, wtang@ntu.edu.sg. Web: http://www3.ntu.edu.sg/home/wtang/
      Skills measurement and enhancement in microsurgery
      Robotics assisted rehabilitation (for stroke)

Dr Lin's research interest includes bioinformatics, biomedical imaging and visualization, high-
performance computing. Contact: Dr Lin Feng, Associate Professor and Programme Director
Digital Media Technology, ASFLIN@ntu.edu.sg Web:
      Collaborative Creation and Application of Interactive Digital Media Over the Internet
      Creating an in Vivo Navigational Cellular Fluorescene Imaging system with Dynamically
       Optimized Endomicroscopy
      Dynamically Adaptable Neurocomputer and its Application to Recognition of Steroid
       Hormone Response Elements
      Real-Time Diagnostic Endoscopy

Dr. Koh Tong San’s research interests include Medical Functional Imaging, Physiological Modeling and
the Properties of Semiconductor Quantum Structures. Contact: Dr. KOH Tong San, Associate
Professor of School of Electrical & Electronic Engineering, etskoh@ntu.edu.sg Web:
     Dynamic Physiological Imaging and Quantification of Tumor Microcirculation
     Principal Investigator, “In-Vivo Assessment of Neo-Angiogenesis and Microcirculatory
        Characteristics of Breast Carcinoma using Dynamic Contrast-Enhanced Magnetic Resonance
        Imaging with Correlations to Histopathology”

Amaranth Medical Pte Ltd is a spin-off from NTU, founded for developing and testing fully
biodegradable stent technology. Amaranth's technology was developed over several years
by a team of researchers led by Professor Freddy Boey and Professor Subbu Venkatraman at
Nanyang Technological University ("NTU") in Singapore. Professor Boey is the Chair of the
School of Materials Science and Engineering at NTU and has many years of experience in
materials development and engineering. Professor Venkatraman's notable career in polymer
science includes over 20 years of product development experience with Silicon Valley
companies, including Alza and Raychem, and he is now the Associate Chair of the School of
Materials Science and Engineering at NTU. The company has been granted a worldwide
exclusive license to this technology by NTU.
Amaranth was originally seeded in Singapore by Bio*One Capital Pte Ltd in 2005. The
company's research, development and manufacturing facilities are located in Singapore,
while the headquarters of the company are currently located in the offices of Charter Life
Sciences in Palo Alto, California. Fred M. Schwarzer, managing director of Charter Life
Sciences, serves as the chairman of Amaranth, and a search is ongoing for a chief executive
officer of the company.
4. Collaboration interest, future perspectives.

There is great interest and synergy with NIMIT in the Netherlands. Delft is well-known for
their capabilities in producing miniaturized tools and NOTES is an important topic in Delft as
well, this synergizes very well with Dr. Phee’s NOTES endoscopic surgical robot which
requires research on the tooling side too.
Rehabilitation research is under funded world round, with most funds being aimed at
medical research. With two IMDI.NL Core centers aimed at rehabilitation, the Netherlands
may be one of the few countries that invests in this field and could have an international
impact in the field.

Future directions.
Next year NTU in collaboration with TTSH will form a new school of medicine. Combining
TTSH’s strong background in rehabilitation from stroke and brain injury.

5. Sources

Patent analysis
National Heart Center

1. General information
Staff               754 (FY 2008)
Website             http://www.nhcs.com.sg/Pages/Home.aspx
Description         The National Heart Centre Singapore is dedicated to providing
                    excellence in healthcare as the national and regional referral
                    centre for cardiovascular disease through cost-effective and best
                    care possible at the best value.
                    Each year, 100,000 patients seek treatment at the National Heart
                    Centre Singapore (NHCS). As a 185-bed national centre for
                    cardiovascular medicine in Singapore, NHCS provides a one-stop
                    comprehensive preventive, diagnostic, therapeutic and
                    rehabilitative cardiac services.
                    They have the largest heart specialists group in Singapore and s ees
                    the highest volume of heart patients locally. The clinical outcomes
                    for heart attack treatment, balloon angioplasty with stenting and
                    coronary bypass surgery are on par with international standards.
                    The National Heart Centre Singapore is a member of SingHealth,
                    the largest healthcare group in Singapore. The group consists of 3
                    Hospitals (Singapore General Hospital, Changi General Hospital, KK
                    Women's and Children's Hospital), 5 National Specialty Centres
                    (National Heart Centre Singapore, National Cancer Centre
                    Singapore, National Dental Centre Singapore, National
                    Neuroscience Institute and Singapore National Eye Centre) and a
                    network of 9 Polyclinics.
2. Key Research

Research and Development Unit (RDU)
National Heart Centre Singapore is dedicated to the pursuit of the basic life sciences. The
RDU's focus and mandate is to translate basic cardiovascular sciences research into
improved patient care. In line with this vision, the RDU integrates, collaborates and
synchronises research across disciplines: eg. cardiologists and engineers, scientists and
clinicians, cardiologists with other specialists, principal investigators with Industry and
government agencies.
The stated mission of the RDU is 'To facilitate the identification of innovative and promising
ideas through the rigours of the research process, and to deliver successful ones to the
practising cardiologist and patient'. Contact: Dr Philip Wong, Director Research and
Development Unit, Website: http://www.nhcs.com.sg/research/research/Pages/Home.aspx

      Stem cell work
      Tissue engineering and development of minimally invasive methods of catheter-
       based delivery for cellular therapeutics
      Developing a quantitative computational approach for comprehensive assessment of
       left ventricular remodelling after myocardial infarction

3. Collaboration

NHC welcomes collaborations, local and overseas, institutional or commercial, to promote
and develop basic and translational research.

4. Sources

BEP programme
National University of Singapore

1. Contact Information
Contact name             Dr. Jui Lim
Position                 Executive Director MERCI
Address                  5 Lower Kent Ridge Road, Singapore 119074
Tel./Fax.                65 6772 5382/ 65 6777 8427
e-mail                   juilim@nus.edu.sg

2. General information
Endowment           S$1.447 billion
Faculty             1,944 (AY 2007-08)
Website             http://www.nus.edu.sg/
Description         The National University of Singapore (NUS) is Singapore's oldest
                    university. It is the largest university in the country in terms of
                    student enrollment and curriculum offered..
                    In 2010 the QS World University Rankings ranked NUS 31st in the
                    world. It was ranked the 3rd Asian University by the QS Asian
                    University Rankings for 2010, which employs a different
                    methodology from their global rankings.
                    The Faculty of Engineering (FOE) is the largest faculty in the
                    university. FOE departments and divisions include: Bioengineering;
                    Chemical & Biomolecular Engineering; Electrical & Computer
                    Engineering; Engineering Science Programme, Industrial &
                    Systems Engineering; Materials Science & Engineering, Mechanical
                    Engineering, and division of Engineering and Technology
                    Among the major research focuses at NUS are biomedical and life
                    sciences, physical sciences, engineering, nanoscience and
                    nanotechnology, materials science and engineering,
                    infocommunication and infotechnology, humanities and social
                    sciences, and defence-related research. One of several niche
                    research areas of strategic importance to Singapore being
                    undertaken at NUS is bioengineering. Initiatives in this area
                    include bioimaging, tissue engineering and tissue modulation.

3. Key Research

The Medical Engineering Research and Commercialization Initiative (MERCI) is an initiative of
the NUS Department of Surgery. MERCI aims to be a platform to support innovation, to
convert research into medical devices and to commercialize these medical devices.
Important aspect is the feasibility of implementation, e.g. aiming for niche tec hnologies that
add to rather than compete with established players, developing tools that will not require
the large infrastructure a small university group is lacking. Dr. Jui Lim also is Programme
Director for the Singapore-Stanford Biodesign program. Contact: Dr. Jui Lim, executive
director, juilim@nus.edu.sg. Web: www.nus.edu.sg
      Diabetes
      Flow sensors for stents
      Pressure sensing guidewires for FFR measurements
      Non-metallic, bio-degradable stents

The Optical Bioimaging Laboratory is located in the Division of Bioengineering. The research
laboratory is headed by Prof. Colin Sheppard, and there are another two principal
investigators (Dr. Huang Zhiwei, Dr. Chen Nanguang) where diverse areas of research topics
are investigated. Through the interfacing element of light, they aim to have deeper
understanding of fundamental science behind biological organism and process; they also
seek to innovate and develop new instrumentation for imaging and diagnostic applications
in clinical research. The work can be summarized into three major areas: Microscopy,
Tomography and Spectroscopy. Contact: Dr. Colin Sheppard, Head Division of Bioengineering,
colin@nus.edu.sg, website: http://www.bioeng.nus.edu.sg/optbioimaging/index.asp
     Colin Sheppard: Confocal microscopy, Second harmonic generation microscopy,
         Quantitative phase imaging, Surface plasmon resonance
     Huang Zhiwei: Biophotonics in biomedical engineering and sciences, Biomedical
         spectroscopy, microscopy and imaging, Laser interactions with tissue and cells,
         Optical coherence microscopy in biomedicine, Advanced optical devices and
     Chen Nanguang: Diffuse optical tomography, Optical coherence tomography, Focal
         modulation microscopy, Time-resolved optical spectroscopy and imaging

The NUS Nano Biomechanics Lab focuses on cell and molecular biomechanics of human
diseases such as malaria and cancer, as well as the mechanics and applications of polymeric
nanobiomaterials. Prof Lim Chwee Teck of the Division of Bioengineering, together with his
student TAN Swee Jin developed the CTC Microfiltration biochip, a medical device that is
able to trap rare circulating tumour cells (CTCs) from just 1 ml of blood obtained from the
patient. The technology is commercialized by Clearbridge Biomedics, a spin-off from the lab.
Contact: Dr. Lim Chwee Teck, lab head, ctlim@nus.edu.sg. Webs ite:
     Mechanics based microdevices for disease detection & diagnosis


Welch Allyn

1. General information
Website             http://www.welchallyn.com/
Description         Welch Allyn, Inc. was founded in 1915 and is a manufacturer of
                    medical diagnostic devices, cardiac defibrillators, patient
                    monitoring systems, and miniature precision lamps.
                    Headquartered in Skaneateles, New York, USA, Welch Allyn
                    employs more than 2,300 people and has manufacturing, sales,
                    and distribution facilities located throughout the world.
                    Welch Allyn is still family owned and based primarily in the United
                    States. This year (2010) they moved their R&D center in Singapore
                    to a larger location in Alexandra Techno Park. There they plan to
                    design next generation digital connected products specifically for
                    Asian and emerging markets.

2. Key Research

Key research is aimed at next generation digital connected products specifically for Asian
and emerging markets.
Earlier this year, the company will highlighted a new radio that was designed specifically for
the medical market and operates on hospitals' existing wireless systems using 802.11 a/b/g
technology. The radio is currently available for the Welch Allyn Spot Vital Signs LXi —one of
the industry's fastest multi-parameter spot-check devices that can be customized for use in a
variety of clinical settings. The wireless Spot Vital Signs LXi transmits vital signs data to an
EHR through the company's Connex Data Management software—eliminating the need for
clinicians to manually input data. The new 802.11 radio will also be incorporated into the
company's next-generation products currently in development. Patent applied for:
     A portable vital signs measurement instrument and method of use thereof.

3. Sources

Patent analysis

To top